|
YTD 2019
|
Q3 2019
|
||||||
|
$m
|
% change
|
$m
|
% change
|
||||
|
Actual
|
CER
|
Actual
|
CER
|
||||
Product Sales
|
17,315
|
13
|
17
|
6,132
|
16
|
18
|
||
Collaboration Revenue
|
405
|
3
|
6
|
274
|
n/m
|
n/m
|
||
Total Revenue
|
17,720
|
13
|
17
|
6,406
|
20
|
22
|
||
Reported4 Operating
Profit
|
2,347
|
2
|
3
|
757
|
(11)
|
(13)
|
||
Core5 Operating
Profit
|
4,891
|
41
|
42
|
1,880
|
43
|
41
|
||
|
|
|
|
|
|
|
||
Reported EPS6
|
$0.79
|
(11)
|
(15)
|
$0.23
|
(33)
|
(38)
|
||
Core EPS
|
$2.61
|
39
|
38
|
$0.99
|
40
|
36
|
||
|
|
|
|
|
|
|
|
|
Regulatory
approvals
|
- Tagrisso -
NSCLC (1st line, EGFRm): regulatory approval (CN)
- Farxiga/Forxiga -
T2D10 CVOT:
regulatory approval (US, EU)
- roxadustat -
anaemia of CKD11, NDD12: regulatory
approval (CN)
- Fasenra Pen -
severe eosinophilic asthma; auto-injector and self-administration:
regulatory approval (US)
|
Regulatory
submissions and/or acceptances
|
- Lynparza -
pancreatic cancer (1st line, BRCAm): regulatory submission
acceptance (US, EU)
- Calquence -
CLL13:
regulatory submission under review (US)
- trastuzumab
deruxtecan - advanced/refractory, metastatic breast cancer
(HER214-positive):
regulatory submission acceptance (US, JP); Priority Review
designation (US)
- Brilinta/Brilique -
CAD15/T2D
CVOT: regulatory submission acceptance (US, EU)
|
Major
Phase
III data readouts or other significant developments
|
- Tagrisso -
NSCLC (1st line, EGFRm): met Phase III key secondary endpoint
(OS16)
- Imfinzi +
treme - NSCLC (1st line) (NEPTUNE): did not meet Phase III primary
endpoint
- Lynparza -
ovarian cancer (1st line) (PAOLA-1): met Phase III primary
endpoint
- Lynparza -
prostate cancer (2nd line, castration-resistant): met Phase III
primary endpoint
- Calquence -
CLL: Breakthrough Therapy Designation (US)
- Farxiga -
HF17 CVOT: met
Phase III primary endpoint; Fast Track designation
(US)
- Farxiga -
CKD: Fast Track designation (US)
- Qtrilmet -
T2D: positive opinion (EU)
- PT010
- COPD18 (ETHOS): met
Phase III primary endpoint
- PT010
- COPD: complete response letter (US)
- Fasenra -
eosinophilic oesophagitis: Orphan Drug Designation
(US)
- anifrolumab
- lupus (SLE19) (TULIP 2): met
Phase III primary endpoint
|
Timing
|
News
flow
|
Q4 2019
|
- Imfinzi -
unresectable, Stage III NSCLC (PACIFIC): regulatory decision
(CN)
- Imfinzi +/-
treme - NSCLC (1st line) (POSEIDON): data readout, regulatory
submission
- Imfinzi +/-
treme - SCLC[20]:
regulatory submission
- Lynparza -
ovarian cancer (1st line, BRCAm) (SOLO-1): regulatory decision
(CN)
- Lynparza -
pancreatic cancer (1st line, BRCAm): regulatory decision
(US)
- selumetinib
- NF1[21]:
regulatory submission (US)
- roxadustat
- anaemia of CKD: regulatory submission (US)
- Symbicort -
mild asthma: regulatory submission (CN)
- PT010
- COPD: regulatory decision (CN)
|
H1 2020
|
- Imfinzi +/-
treme - head & neck cancer (1st line): data readout, regulatory
submission
- Imfinzi +/-
treme - bladder cancer (1st line) (DANUBE): data readout,
regulatory submission
- Lynparza -
breast cancer (BRCAm): regulatory decision (CN)
- Lynparza -
ovarian cancer (1st line) (PAOLA-1): regulatory
submission
- Lynparza -
prostate cancer (2nd line, castration-resistant): regulatory
submission
- Lynparza +
cediranib - ovarian cancer (2nd line): data readout
- trastuzumab
deruxtecan - advanced/refractory, metastatic breast cancer
(HER2-positive): regulatory decision (US, JP)
- trastuzumab
deruxtecan - advanced/refractory, metastatic gastric cancer
(HER2-positive): data readout, regulatory submission
(JP)
- Calquence -
CLL: regulatory decision (US)
- Calquence -
CLL: regulatory submission (EU, JP)
- selumetinib
- NF1: regulatory submission (EU)
- Forxiga -
T2D CVOT: regulatory decision (CN)
- Farxiga -
HF CVOT: regulatory submission
- Brilinta -
stroke (THALES): data readout
- Lokelma -
hyperkalaemia: regulatory decision (JP, CN)
- Symbicort -
mild asthma: regulatory submission (EU)
- Bevespi -
COPD: regulatory decision (CN)
- PT010
- COPD: regulatory decision (US, EU)
|
H2 2020
|
- Imfinzi -
neo-adjuvant NSCLC: data readout
- Imfinzi -
unresectable, Stage III NSCLC (PACIFIC-2): data
readout
- Imfinzi +/-
treme - liver cancer (1st line): data readout
- Lynparza -
ovarian cancer (3rd line, BRCAm): regulatory submission
(US)
- Lynparza -
pancreatic cancer (1st line, BRCAm): regulatory decision
(EU)
- Brilinta -
stroke (THALES): regulatory submission
- Epanova -
hypertriglyceridaemia CVOT: data readout
- roxadustat
- anaemia of myelodysplastic syndrome: data readout
- Fasenra -
nasal polyposis: data readout
- PT027
- asthma: data readout
- tezepelumab
- severe asthma: data readout
- anifrolumab
- lupus (SLE): regulatory submission
|
2021
|
- Imfinzi -
neo-adjuvant NSCLC: regulatory submission
- Imfinzi -
adjuvant NSCLC: data readout, regulatory submission
- Imfinzi -
unresectable, Stage III NSCLC (PACIFIC-2): regulatory
submission
- Imfinzi -
unresectable, Stage III NSCLC (PACIFIC-5): data
readout
- Imfinzi -
NSCLC (1st line) (PEARL): data readout, regulatory
submission
- Imfinzi +/-
treme - limited-disease stage SCLC: data readout
- Imfinzi +/-
treme - bladder cancer (1st line) (NILE): data readout, regulatory
submission
- Imfinzi +/-
treme - liver cancer (1st line): regulatory submission
- Imfinzi -
liver cancer (locoregional): data readout, regulatory
submission
- Imfinzi -
biliary tract cancer: data readout
- Lynparza -
adjuvant breast cancer: data readout, regulatory
submission
- Lynparza -
prostate cancer (1st line, castration-resistant): data readout,
regulatory submission
- Lynparza +
cediranib - ovarian cancer (2nd line): regulatory
submission
- trastuzumab
deruxtecan - advanced/refractory, metastatic breast cancer
(HER2-positive, 3rd line+): data readout, regulatory
submission
- trastuzumab
deruxtecan - advanced/refractory, metastatic breast cancer
(HER2-positive, 2nd line): data readout
- trastuzumab
deruxtecan - advanced/refractory, metastatic breast cancer
(HER2-low): data readout
- Farxiga -
chronic kidney disease: data readout, regulatory
submission
- Epanova -
hypertriglyceridaemia CVOT: regulatory submission
- roxadustat
- anaemia of myelodysplastic syndrome: regulatory
submission
- Fasenra -
nasal polyposis: regulatory submission
- PT027
- asthma: regulatory submission
- tezepelumab
- severe asthma: regulatory submission
|
Investor
Relations
|
|
|
|
Thomas
Kudsk Larsen
|
|
+44 203
749 5712
|
|
Henry
Wheeler
|
Oncology
|
+44 203
749 5797
|
|
Christer
Gruvris
|
BioPharmaceuticals
(CV, Metabolism)
|
+44 203
749 5711
|
|
Nick
Stone
|
BioPharmaceuticals
(Renal), ESG
|
+44 203
749 5716
|
|
Josie
Afolabi
|
BioPharmaceuticals
(Respiratory), other medicines
|
+44 203
749 5631
|
|
Craig
Marks
|
Finance,
fixed income
|
+44
7881 615 764
|
|
Jennifer
Kretzmann
|
Corporate
access, retail investors
|
+44 203
749 5824
|
|
US
toll-free
|
|
+1 866
381 7277
|
|
Media
Relations
|
|
|
|
Gonzalo
Viña
|
|
+44 203
749 5916
|
|
Rob
Skelding
|
Oncology
|
+44 203
749 5821
|
|
Rebecca
Einhorn
|
Oncology
|
+1 301 518 4122
|
|
Matt
Kent
|
BioPharmaceuticals
|
+44 203
749 5906
|
|
Jennifer
Hursit
|
Other
|
+44
7384 799 726
|
|
Christina Malmberg
Hägerstrand
|
Sweden
|
+46 8
552 53 106
|
|
Michele
Meixell
|
US
|
+1 302
885 2677
|
|
|
|
|
|
|
YTD 2019
|
Q3 2019
|
|||||
|
$m
|
% change
|
$m
|
% change
|
|||
|
Actual
|
CER
|
Actual
|
CER
|
|||
Product Sales
|
17,315
|
13
|
17
|
6,132
|
16
|
18
|
|
Collaboration Revenue
|
405
|
3
|
6
|
274
|
n/m
|
n/m
|
|
|
|
|
|
|
|
|
|
Total Revenue
|
17,720
|
13
|
17
|
6,406
|
20
|
22
|
|
|
|
|
|
|
|
|
|
|
YTD 2019
|
Q3 2019
|
||||||||
|
$m
|
% of total
|
% change
|
$m
|
% of total
|
% change
|
||||
|
Actual
|
CER
|
Actual
|
CER
|
||||||
Oncology
|
6,393
|
37
|
50
|
54
|
2,334
|
38
|
46
|
48
|
||
|
|
|
|
|
|
|
|
|
||
BioPharmaceuticals
|
7,061
|
41
|
9
|
13
|
2,432
|
40
|
12
|
14
|
||
New CVRM
|
3,207
|
19
|
11
|
14
|
1,113
|
18
|
8
|
11
|
||
Respiratory
|
3,854
|
22
|
9
|
13
|
1,319
|
22
|
15
|
18
|
||
|
|
|
|
|
|
|
|
|
||
Other medicines
|
3,861
|
22
|
(16)
|
(12)
|
1,366
|
22
|
(9)
|
(7)
|
||
|
|
|
|
|
|
|
|
|
||
Total
|
17,315
|
100
|
13
|
17
|
6,132
|
100
|
16
|
18
|
||
|
|
|
|
|
|
|
|
|
|
|
Medicine
|
Therapy area
|
YTD 2019
|
Q3 2019
|
||||||
$m
|
% of total
|
% change
|
$m
|
% of total
|
% change
|
||||
Actual
|
CER
|
Actual
|
CER
|
||||||
Tagrisso
|
Oncology
|
2,305
|
13
|
82
|
86
|
891
|
15
|
76
|
78
|
Symbicort
|
Respiratory
|
1,783
|
10
|
(7)
|
(4)
|
613
|
10
|
(1)
|
1
|
Brilinta
|
CVRM
|
1,153
|
7
|
22
|
26
|
416
|
7
|
24
|
27
|
Nexium
|
Other medicines
|
1,130
|
7
|
(14)
|
(11)
|
374
|
6
|
(11)
|
(10)
|
Farxiga
|
CVRM
|
1,124
|
6
|
13
|
17
|
398
|
6
|
12
|
14
|
Pulmicort
|
Respiratory
|
1,053
|
6
|
17
|
23
|
337
|
6
|
28
|
31
|
Imfinzi
|
Oncology
|
1,045
|
6
|
n/m
|
n/m
|
412
|
7
|
n/m
|
n/m
|
Crestor
|
CVRM
|
982
|
6
|
(9)
|
(5)
|
337
|
6
|
(4)
|
(2)
|
Lynparza
|
Oncology
|
847
|
5
|
93
|
98
|
327
|
5
|
94
|
96
|
Faslodex
|
Oncology
|
726
|
4
|
(4)
|
(1)
|
205
|
3
|
(20)
|
(19)
|
Total
|
|
12,149
|
70
|
22
|
26
|
4,311
|
70
|
24
|
26
|
|
YTD 2019
|
Q3 2019
|
||||||||
|
|
|
% change
|
|
|
% change
|
||||
|
$m
|
% of total
|
Actual
|
CER
|
$m
|
% of total
|
Actual
|
CER
|
||
Initial Collaboration Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
||
|
|
|
|
|
|
|
|
|
||
Ongoing Collaboration Revenue
|
405
|
100
|
45
|
49
|
274
|
100
|
n/m
|
n/m
|
||
Royalties
|
45
|
11
|
17
|
23
|
13
|
5
|
(27)
|
(25)
|
||
Milestones/other
|
360
|
89
|
49
|
53
|
261
|
95
|
n/m
|
n/m
|
||
|
|
|
|
|
|
|
|
|
||
Total
|
405
|
100
|
3
|
6
|
274
|
100
|
n/m
|
n/m
|
||
|
|
|
|
|
|
|
|
|
|
|
Therapy area
|
Medicine
|
YTD 2019
|
|||
$m
|
% of
total
|
% change
|
|||
Actual
|
CER
|
||||
Oncology
|
Tagrisso
|
2,305
|
13
|
82
|
86
|
Imfinzi
|
1,045
|
6
|
n/m
|
n/m
|
|
Lynparza
|
847
|
5
|
93
|
98
|
|
Iressa
|
343
|
2
|
(16)
|
(11)
|
|
Calquence
|
108
|
1
|
n/m
|
n/m
|
|
Legacy:
|
|
|
|
|
|
Faslodex
|
726
|
4
|
(4)
|
(1)
|
|
Zoladex
|
617
|
4
|
8
|
15
|
|
Arimidex
|
174
|
1
|
5
|
10
|
|
Casodex
|
157
|
1
|
2
|
6
|
|
Others
|
68
|
-
|
(26)
|
(24)
|
|
Total Oncology
|
6,393
|
37
|
50
|
54
|
|
BioPharmaceuticals: CVRM
|
Farxiga
|
1,124
|
6
|
13
|
17
|
Brilinta
|
1,153
|
7
|
22
|
26
|
|
Bydureon
|
410
|
2
|
(8)
|
(7)
|
|
Onglyza
|
396
|
2
|
-
|
4
|
|
Byetta
|
83
|
-
|
(12)
|
(10)
|
|
Other diabetes
|
36
|
-
|
33
|
35
|
|
Lokelma
|
6
|
-
|
n/m
|
n/m
|
|
Legacy:
|
|
|
|
|
|
Crestor
|
982
|
6
|
(9)
|
(5)
|
|
Seloken/Toprol-XL
|
570
|
3
|
3
|
10
|
|
Atacand
|
161
|
1
|
(20)
|
(16)
|
|
Others
|
199
|
1
|
(13)
|
(9)
|
|
BioPharmaceuticals: total CVRM
|
5,121
|
30
|
3
|
7
|
|
BioPharmaceuticals: Respiratory
|
Symbicort
|
1,783
|
10
|
(7)
|
(4)
|
Pulmicort
|
1,053
|
6
|
17
|
23
|
|
Fasenra
|
498
|
3
|
n/m
|
n/m
|
|
Daliresp/Daxas
|
157
|
1
|
16
|
17
|
|
Duaklir
|
55
|
-
|
(24)
|
(20)
|
|
Tudorza/Eklira
|
50
|
-
|
(45)
|
(42)
|
|
Bevespi
|
30
|
-
|
32
|
32
|
|
Breztri
|
1
|
-
|
n/m
|
n/m
|
|
Others
|
226
|
1
|
(3)
|
2
|
|
BioPharmaceuticals: total Respiratory
|
3,854
|
22
|
9
|
13
|
|
Other medicines
|
Nexium
|
1,130
|
7
|
(14)
|
(11)
|
Synagis
|
295
|
2
|
(29)
|
(29)
|
|
Losec/Prilosec
|
217
|
1
|
3
|
8
|
|
Seroquel XR/IR
|
151
|
1
|
(51)
|
(49)
|
|
Movantik/Moventig
|
72
|
-
|
(15)
|
(15)
|
|
Others
|
83
|
-
|
(54)
|
(48)
|
|
Total other medicines
|
1,948
|
11
|
(22)
|
(20)
|
|
|
Total Product Sales
|
17,315
|
100
|
13
|
17
|
Therapy area
|
Medicine
|
Q3 2019
|
|||
$m
|
% of
total
|
% change
|
|||
Actual
|
CER
|
||||
Oncology
|
Tagrisso
|
891
|
15
|
76
|
78
|
Imfinzi
|
412
|
7
|
n/m
|
n/m
|
|
Lynparza
|
327
|
5
|
94
|
96
|
|
Iressa
|
91
|
1
|
(31)
|
(29)
|
|
Calquence
|
44
|
1
|
n/m
|
n/m
|
|
Legacy:
|
|
|
|
|
|
Faslodex
|
205
|
3
|
(20)
|
(19)
|
|
Zoladex
|
226
|
4
|
17
|
21
|
|
Arimidex
|
63
|
1
|
15
|
17
|
|
Casodex
|
52
|
1
|
3
|
5
|
|
Others
|
20
|
-
|
(27)
|
(26)
|
|
Total Oncology
|
2,334
|
38
|
46
|
48
|
|
BioPharmaceuticals: CVRM
|
Farxiga
|
398
|
6
|
12
|
14
|
Brilinta
|
416
|
7
|
24
|
27
|
|
Onglyza
|
127
|
2
|
(9)
|
(7)
|
|
Bydureon
|
127
|
2
|
(16)
|
(16)
|
|
Byetta
|
28
|
-
|
(19)
|
(18)
|
|
Other diabetes
|
14
|
-
|
38
|
44
|
|
Lokelma
|
4
|
-
|
n/m
|
n/m
|
|
Legacy:
|
|
|
|
|
|
Crestor
|
337
|
6
|
(4)
|
(2)
|
|
Seloken/Toprol-XL
|
177
|
3
|
(1)
|
3
|
|
Atacand
|
55
|
1
|
(15)
|
(11)
|
|
Others
|
65
|
1
|
(8)
|
(6)
|
|
BioPharmaceuticals: total CVRM
|
1,749
|
29
|
3
|
6
|
|
BioPharmaceuticals: Respiratory
|
Symbicort
|
613
|
10
|
(1)
|
1
|
Pulmicort
|
337
|
6
|
28
|
31
|
|
Fasenra
|
202
|
3
|
n/m
|
n/m
|
|
Daliresp/Daxas
|
53
|
1
|
2
|
3
|
|
Duaklir
|
18
|
-
|
(21)
|
(19)
|
|
Tudorza/Eklira
|
17
|
-
|
(4)
|
-
|
|
Bevespi
|
10
|
-
|
4
|
4
|
|
Breztri
|
1
|
-
|
n/m
|
n/m
|
|
Others
|
67
|
1
|
(5)
|
-
|
|
BioPharmaceuticals: total Respiratory
|
1,319
|
22
|
15
|
18
|
|
Other medicines
|
Nexium
|
374
|
6
|
(11)
|
(10)
|
Synagis
|
146
|
2
|
(11)
|
(11)
|
|
Losec/Prilosec
|
73
|
1
|
10
|
13
|
|
Seroquel XR/IR
|
82
|
1
|
5
|
6
|
|
Movantik/Moventig
|
25
|
-
|
(22)
|
(23)
|
|
Others
|
31
|
1
|
(55)
|
(59)
|
|
Total other medicines
|
731
|
12
|
(12)
|
(11)
|
|
|
Total Product Sales
|
6,132
|
100
|
16
|
18
|
Global Sales
|
YTD 2019
|
Q3 2019
|
||||||
$m
|
% of total
|
% change
|
$m
|
% of total
|
% change
|
|||
Actual
|
CER
|
Actual
|
CER
|
|||||
Emerging Markets
|
6,074
|
35
|
19
|
26
|
2,123
|
35
|
25
|
29
|
China
|
3,691
|
21
|
30
|
37
|
1,283
|
21
|
35
|
40
|
Ex-China
|
2,382
|
14
|
5
|
12
|
839
|
14
|
12
|
15
|
|
|
|
|
|
|
|
|
|
US
|
5,688
|
33
|
18
|
18
|
2,025
|
33
|
17
|
17
|
|
|
|
|
|
|
|
|
|
Europe
|
3,168
|
18
|
(4)
|
2
|
1,139
|
19
|
1
|
4
|
|
|
|
|
|
|
|
|
|
Established RoW
|
2,385
|
14
|
17
|
19
|
845
|
14
|
21
|
19
|
Japan
|
1,830
|
11
|
29
|
29
|
657
|
11
|
31
|
27
|
Canada
|
345
|
2
|
(4)
|
(1)
|
120
|
2
|
5
|
5
|
Other Established RoW
|
211
|
1
|
(18)
|
(12)
|
69
|
1
|
(16)
|
(11)
|
|
|
|
|
|
|
|
|
|
Total
|
17,315
|
100
|
13
|
17
|
6,132
|
100
|
16
|
18
|
Emerging Markets
|
YTD 2019
|
Q3 2019
|
||||||
$m
|
% of total
|
% change
|
$m
|
% of total
|
% change
|
|||
Actual
|
CER
|
Actual
|
CER
|
|||||
Oncology
|
1,665
|
27
|
42
|
51
|
617
|
29
|
45
|
49
|
|
|
|
|
|
|
|
|
|
BioPharmaceuticals
|
3,644
|
60
|
16
|
23
|
1,240
|
58
|
20
|
24
|
CVRM
|
2,225
|
37
|
11
|
18
|
777
|
37
|
16
|
19
|
Respiratory
|
1,419
|
23
|
24
|
31
|
463
|
22
|
28
|
32
|
|
|
|
|
|
|
|
|
|
Other medicines
|
765
|
13
|
(4)
|
1
|
266
|
13
|
10
|
19
|
|
|
|
|
|
|
|
|
|
Total Emerging Markets
|
6,074
|
100
|
19
|
26
|
2,123
|
100
|
25
|
29
|
US
|
YTD 2019
|
Q3 2019
|
||||
$m
|
% of total
|
% change
|
$m
|
% of total
|
% change
|
|
Oncology
|
2,538
|
45
|
57
|
917
|
45
|
40
|
|
|
|
|
|
|
|
BioPharmaceuticals
|
2,805
|
49
|
7
|
964
|
48
|
4
|
CVRM
|
1,622
|
29
|
1
|
537
|
27
|
(6)
|
Respiratory
|
1,183
|
21
|
15
|
427
|
21
|
20
|
|
|
|
|
|
|
|
Other medicines
|
345
|
6
|
(41)
|
144
|
7
|
(6)
|
|
|
|
|
|
|
|
Total US
|
5,688
|
100
|
18
|
2,025
|
100
|
17
|
Europe
|
YTD 2019
|
Q3 2019
|
||||||
$m
|
% of total
|
% change
|
$m
|
% of total
|
% change
|
|||
Actual
|
CER
|
Actual
|
CER
|
|||||
Oncology
|
1,027
|
32
|
34
|
42
|
377
|
33
|
44
|
51
|
|
|
|
|
|
|
|
|
|
BioPharmaceuticals
|
1,677
|
53
|
(10)
|
(4)
|
550
|
49
|
(6)
|
(0)
|
CVRM
|
858
|
27
|
(8)
|
(3)
|
292
|
26
|
(3)
|
2
|
Respiratory
|
819
|
26
|
(11)
|
(6)
|
258
|
23
|
(8)
|
(3)
|
|
|
|
|
|
|
|
|
|
Other medicines
|
465
|
15
|
(30)
|
(28)
|
213
|
19
|
(26)
|
(29)
|
|
|
|
|
|
|
|
|
|
Total Europe
|
3,168
|
100
|
(4)
|
2
|
1,139
|
100
|
1
|
4
|
Established RoW
|
YTD 2019
|
Q3 2019
|
||||||
$m
|
% of total
|
% change
|
$m
|
% of total
|
% change
|
|||
Actual
|
CER
|
Actual
|
CER
|
|||||
Oncology
|
1,163
|
49
|
66
|
67
|
423
|
50
|
67
|
63
|
|
|
|
|
|
|
|
|
|
BioPharmaceuticals
|
849
|
36
|
(3)
|
(1)
|
314
|
37
|
6
|
6
|
CVRM
|
416
|
17
|
(2)
|
1
|
143
|
17
|
(4)
|
(3)
|
Respiratory
|
433
|
18
|
(4)
|
(2)
|
171
|
20
|
17
|
16
|
|
|
|
|
|
|
|
|
|
Other medicines
|
373
|
16
|
(19)
|
(16)
|
108
|
13
|
(27)
|
(31)
|
|
|
|
|
|
|
|
|
|
Total Established RoW
|
2,385
|
100
|
17
|
19
|
845
|
100
|
21
|
19
|
|
Reported
|
|||
YTD 2019
|
YTD 2018
|
% change
|
||
$m
|
$m
|
Actual
|
CER
|
|
Product Sales
|
17,315
|
15,281
|
13
|
17
|
Collaboration Revenue
|
405
|
392
|
3
|
6
|
Total Revenue
|
17,720
|
15,673
|
13
|
17
|
|
|
|
|
|
Cost of Sales
|
(3,543)
|
(3,299)
|
7
|
12
|
|
|
|
|
|
Gross Profit
|
14,177
|
12,374
|
15
|
18
|
Gross Profit
Margin[24]
|
79.5%
|
78.4%
|
+1
|
+1
|
|
|
|
|
|
Distribution Expense
|
(247)
|
(238)
|
4
|
10
|
% Total Revenue
|
1.4%
|
1.5%
|
-
|
-
|
R&D Expense
|
(3,968)
|
(3,920)
|
1
|
5
|
% Total Revenue
|
22.4%
|
25.0%
|
+3
|
+3
|
SG&A Expense
|
(8,656)
|
(7,431)
|
16
|
20
|
% Total Revenue
|
48.9%
|
47.4%
|
-1
|
-1
|
Other Operating Income & Expense
|
1,041
|
1,525
|
(32)
|
(31)
|
% Total Revenue
|
5.9%
|
9.7%
|
-4
|
-4
|
|
|
|
|
|
Operating Profit
|
2,347
|
2,310
|
2
|
3
|
Operating Profit Margin
|
13.2%
|
14.7%
|
-1
|
-2
|
Net Finance Expense
|
(948)
|
(970)
|
(2)
|
6
|
Joint Ventures and Associates
|
(91)
|
(77)
|
18
|
21
|
Profit Before Tax
|
1,308
|
1,263
|
4
|
(1)
|
Taxation
|
(358)
|
(222)
|
61
|
54
|
Tax Rate
|
27%
|
18%
|
|
|
Profit After Tax
|
950
|
1,041
|
(9)
|
(13)
|
|
|
|
|
|
EPS
|
$0.79
|
$0.88
|
(11)
|
(15)
|
|
Reported
|
|||
Q3 2019
|
Q3 2018
|
% change
|
||
$m
|
$m
|
Actual
|
CER
|
|
Product Sales
|
6,132
|
5,266
|
16
|
18
|
Collaboration Revenue
|
274
|
74
|
n/m
|
n/m
|
Total Revenue
|
6,406
|
5,340
|
20
|
22
|
|
|
|
|
|
Cost of Sales
|
(1,351)
|
(1,153)
|
17
|
23
|
|
|
|
|
|
Gross Profit
|
5,055
|
4,187
|
21
|
22
|
Gross Profit Margin
|
78.0%
|
78.1%
|
-
|
-1
|
|
|
|
|
|
Distribution Expense
|
(88)
|
(73)
|
20
|
25
|
% Total Revenue
|
1.4%
|
1.4%
|
-
|
-
|
R&D Expense
|
(1,346)
|
(1,279)
|
5
|
8
|
% Total Revenue
|
21.0%
|
24.0%
|
+3
|
+3
|
SG&A Expense
|
(3,199)
|
(2,423)
|
32
|
34
|
% Total Revenue
|
49.9%
|
45.4%
|
-5
|
-4
|
Other Operating Income & Expense
|
335
|
439
|
(24)
|
(23)
|
% Total Revenue
|
5.2%
|
8.2%
|
-3
|
-3
|
|
|
|
|
|
Operating Profit
|
757
|
851
|
(11)
|
(13)
|
Operating Profit Margin
|
11.8%
|
15.9%
|
-4
|
-5
|
Net Finance Expense
|
(316)
|
(330)
|
(4)
|
2
|
Joint Ventures and Associates
|
(32)
|
(44)
|
(27)
|
(21)
|
Profit Before Tax
|
409
|
477
|
(14)
|
(21)
|
Taxation
|
(129)
|
(71)
|
81
|
65
|
Tax Rate
|
32%
|
15%
|
|
|
Profit After Tax
|
280
|
406
|
(31)
|
(36)
|
|
|
|
|
|
EPS
|
$0.23
|
$0.34
|
(33)
|
(38)
|
|
YTD 2019
|
YTD 2018
|
% change
|
|
|
$m
|
$m
|
Actual
|
CER
|
Reported Profit Before Tax
|
1,308
|
1,263
|
4
|
(1)
|
Net Finance Expense
|
948
|
970
|
(2)
|
6
|
Joint Ventures and Associates
|
91
|
77
|
18
|
21
|
Depreciation, Amortisation and Impairment
|
2,119
|
2,091
|
1
|
5
|
|
|
|
|
|
EBITDA
|
4,466
|
4,401
|
1
|
4
|
|
Q3 2019
|
Q3 2018
|
% change
|
|
|
$m
|
$m
|
Actual
|
CER
|
Reported Profit Before Tax
|
409
|
477
|
(14)
|
(21)
|
Net Finance Expense
|
316
|
330
|
(4)
|
2
|
Joint Ventures and Associates
|
32
|
44
|
(27)
|
(21)
|
Depreciation, Amortisation and Impairment
|
716
|
698
|
2
|
5
|
EBITDA
|
1,473
|
1,549
|
(5)
|
(5)
|
|
Reported
|
Restructuring
|
Intangible Asset
Amortisation & Impairments
|
Diabetes Alliance
|
Other[26]
|
Core[27]
|
Core
% change
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
Actual
|
CER
|
|
Gross Profit
|
14,177
|
122
|
69
|
-
|
-
|
14,368
|
14
|
18
|
Gross Profit Margin[28]
|
79.5%
|
|
|
|
|
80.6%
|
+1
|
+1
|
|
|
|
|
|
|
|
|
|
Distribution Expense
|
(247)
|
-
|
-
|
-
|
-
|
(247)
|
4
|
10
|
R&D Expense
|
(3,968)
|
82
|
60
|
-
|
-
|
(3,826)
|
1
|
4
|
SG&A Expense
|
(8,656)
|
147
|
1,009
|
294
|
742
|
(6,464)
|
4
|
8
|
Other Operating Income & Expense
|
1,041
|
-
|
3
|
-
|
16
|
1,060
|
(7)
|
(6)
|
|
|
|
|
|
|
|
|
|
Operating Profit
|
2,347
|
351
|
1,141
|
294
|
758
|
4,891
|
41
|
42
|
Operating Profit Margin
|
13.2%
|
|
|
|
|
27.6%
|
+5
|
+5
|
|
|
|
|
|
|
|
|
|
Net Finance Expense
|
(948)
|
-
|
-
|
216
|
153
|
(579)
|
3
|
13
|
Taxation
|
(358)
|
(74)
|
(240)
|
(106)
|
(136)
|
(914)
|
68
|
68
|
|
|
|
|
|
|
|
|
|
EPS
|
$0.79
|
$0.22
|
$0.69
|
$0.31
|
$0.60
|
$2.61
|
39
|
38
|
|
Reported
|
Restructuring
|
Intangible Asset
Amortisation & Impairments
|
Diabetes Alliance
|
Other26
|
Core27
|
Core
% change
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
Actual
|
CER
|
|
Gross Profit
|
5,055
|
70
|
18
|
-
|
-
|
5,143
|
21
|
22
|
Gross Profit Margin28
|
78.0%
|
|
|
|
|
79.4%
|
-
|
-1
|
|
|
|
|
|
|
|
|
|
Distribution Expense
|
(88)
|
-
|
-
|
-
|
-
|
(88)
|
20
|
25
|
R&D Expense
|
(1,346)
|
18
|
7
|
-
|
-
|
(1,321)
|
6
|
9
|
SG&A Expense
|
(3,199)
|
37
|
327
|
96
|
533
|
(2,206)
|
7
|
9
|
Other Operating Income & Expense
|
335
|
-
|
1
|
-
|
16
|
352
|
(20)
|
(19)
|
|
|
|
|
|
|
|
|
|
Operating Profit
|
757
|
125
|
353
|
96
|
549
|
1,880
|
43
|
41
|
Operating Profit Margin
|
11.8%
|
|
|
|
|
29.3%
|
+5
|
+4
|
|
|
|
|
|
|
|
|
|
Net Finance Expense
|
(316)
|
-
|
-
|
72
|
52
|
(192)
|
(1)
|
5
|
Taxation
|
(129)
|
(27)
|
(75)
|
(35)
|
(116)
|
(382)
|
80
|
75
|
|
|
|
|
|
|
|
|
|
EPS
|
$0.23
|
$0.08
|
$0.20
|
$0.10
|
$0.38
|
$0.99
|
40
|
36
|
|
YTD 2019
|
YTD 2018
|
Change
|
|
$m
|
$m
|
$m
|
Reported Operating Profit
|
2,347
|
2,310
|
37
|
Depreciation, Amortisation and Impairment
|
2,119
|
2,091
|
28
|
|
|
|
|
Increase in Working Capital and Short-Term Provisions
|
(812)
|
(1,741)
|
929
|
Gains on Disposal of Intangible Assets
|
(833)
|
(975)
|
142
|
Non-Cash and Other Movements
|
313
|
(428)
|
741
|
Interest Paid
|
(575)
|
(457)
|
(118)
|
Taxation Paid
|
(965)
|
(406)
|
(559)
|
|
|
|
|
Net Cash Inflow from Operating Activities
|
1,594
|
394
|
1,200
|
Net Cash Inflow before Financing Activities
|
879
|
430
|
449
|
Net Cash Outflow from Financing Activities
|
(1,771)
|
(312)
|
(1,459)
|
|
At
30 Sep 2019
|
At
31 Dec 2018
|
At
30 Sep 2018
|
|
$m
|
$m
|
$m
|
Cash and Cash Equivalents
|
3,967
|
4,831
|
3,420
|
Other Investments
|
909
|
895
|
860
|
|
|
|
|
Cash and Investments
|
4,876
|
5,726
|
4,280
|
|
|
|
|
Overdrafts and Short-Term Borrowings
|
(228)
|
(755)
|
(1,092)
|
Leases[29]
|
(712)
|
-
|
-
|
Current Instalments of Loans
|
-
|
(999)
|
(1,399)
|
Loans Due After One Year
|
(17,218)
|
(17,359)
|
(18,422)
|
|
|
|
|
Interest-Bearing Loans and Borrowings (Gross Debt)
|
(18,158)
|
(19,113)
|
(20,913)
|
|
|
|
|
Net Derivatives
|
(16)
|
384
|
448
|
Net Debt
|
(13,298)
|
(13,003)
|
(16,185)
|
|
Average Exchange
Rates versus USD
|
|
Annual Impact of 5% Strengthening in Exchange Rate versus USD
($m)[30]
|
|||
Currency
|
Primary Relevance
|
FY 2018[31]
|
YTD 2019[32]
|
% change
|
Product Sales
|
Core Operating Profit
|
CNY
|
Product
Sales
|
6.62
|
6.87
|
(4)
|
221
|
126
|
EUR
|
Product
Sales
|
0.85
|
0.89
|
(5)
|
145
|
66
|
JPY
|
Product
Sales
|
110.45
|
109.07
|
1
|
114
|
74
|
Other[33]
|
|
|
|
|
216
|
105
|
GBP
|
Operating
Expense
|
0.75
|
0.79
|
(5)
|
26
|
(72)
|
SEK
|
Operating
Expense
|
8.69
|
9.40
|
(8)
|
4
|
(73)
|
Regulatory
approvals
|
5
|
- Tagrisso -
NSCLC (1st line, EGFRm): regulatory approval (CN)
- Farxiga/Forxiga -
T2D CVOT: regulatory approval (US, EU)
- roxadustat -
anaemia of CKD, NDD: regulatory approval (CN)
- Fasenra Pen -
severe eosinophilic asthma; auto-injector and self-administration:
regulatory approval (US)
|
Regulatory
submissions and/or acceptances
|
6
|
- Lynparza -
pancreatic cancer (BRCAm): regulatory submission acceptance (US,
EU)
- Calquence -
CLL: regulatory submission under review (US)
- trastuzumab
deruxtecan - advanced/refractory, metastatic breast cancer
(HER2-positive): regulatory submission acceptance (US, JP);
Priority Review designation (US)
- Brilinta/Brilique -
CAD/T2D CVOT: regulatory submission acceptance (US,
EU)
|
Major
Phase III data readouts
or
other major developments
|
13
|
- Tagrisso -
NSCLC (1st line, EGFRm): met Phase III key secondary endpoint
(OS)
- Imfinzi +
treme - NSCLC (1st line) (NEPTUNE trial): did not meet Phase III
primary endpoint
- Lynparza -
ovarian cancer (1st line) (PAOLA-1): met Phase III primary
endpoint
- Lynparza -
prostate cancer (2nd line, castration-resistant): met Phase III
primary endpoint
- Calquence -
CLL: Breakthrough Therapy Designation (US)
- Farxiga -
HF CVOT: met Phase III primary endpoint; Fast Track designation
(US)
- Farxiga -
CKD: Fast Track designation (US)
- Qtrilmet -
T2D: positive opinion (EU)
- PT010
- COPD (ETHOS): met Phase III primary endpoint
- PT010
- COPD: complete response letter (US)
- Fasenra -
eosinophilic oesophagitis: Orphan Drug Designation
(US)
- anifrolumab
- SLE (TULIP 2): met Phase III primary endpoint
|
New
molecular
entities
and major lifecycle medicines in Phase III trials or under
regulatory review
|
16
|
Oncology
- Tagrisso -
NSCLC
- Imfinzi -
multiple cancers
- Lynparza -
multiple cancers
- trastuzumab
deruxtecan - breast and other cancers
- capivasertib
- breast cancer
- Calquence -
blood cancers
- tremelimumab
- multiple cancers
- selumetinib -
NF1[36]
- savolitinib
- NSCLC36
CVRM
- roxadustat
- anaemia of CKD
Respiratory
(and immunology)
- Fasenra
- multiple indications
- Breztri -
COPD
- PT027
- asthma
- tezepelumab
- severe asthma
- nirsevimab
- lower respiratory tract infection
- anifrolumab
- lupus
|
Total
projects
in
clinical pipeline
|
144
|
|
Trial
|
Population
|
Design
|
Timeline
|
Status
|
Phase
III
ADAURA
|
Adjuvant
EGFRm NSCLC
|
Placebo
or Tagrisso
|
FPCD[40]
Q4
2015
LPCD[41]
Q1
2019
First
data anticipated
2021+[42]
|
Recruitment
completed
|
Phase
III
LAURA
|
Locally-advanced,
unresectable EGFRm NSCLC
|
Placebo
or Tagrisso
|
FPCD
Q3
2018
First
data anticipated
2021+
|
Recruitment
ongoing
|
Phase
III
FLAURA2
|
1st-line
EGFRm NSCLC
|
Tagrisso or Tagrisso + platinum-based
chemotherapy doublet
|
FPCD
Q3
2019
First
data anticipated
2021+
|
Recruitment
ongoing
|
Phase
II
SAVANNAH
|
EGFRm,
MET+ locally-advanced or metastatic NSCLC patients who have
progressed on Tagrisso
|
Tagrisso + savolitinib
|
FPCD
Q1
2019
First
data anticipated
2021+
|
Recruitment
ongoing
|
Phase
II
ORCHARD
|
1st-line
EGFRm NSCLC post Tagrisso
|
SoC
chemotherapy or Tagrisso
+savolitinib or Tagrisso + Iressa or Tagrisso + necitumumab
or Imfinzi +
chemotherapy
|
FPCD
Q2
2019
First
data anticipated
2021+
|
Recruitment
ongoing
|
Trial
|
Population
|
Design
|
Timeline
|
Status
|
Phase
III
AEGEAN
|
Neo-adjuvant
(before surgery) NSCLC
|
SoC
chemotherapy +/- Imfinzi,
followed
by
surgery,
followed by placebo or Imfinzi
|
FPCD
Q1
2019
First
data anticipated
H2
2020
|
Recruitment
ongoing
|
Phase
III
ADJUVANT BR.31[43]
|
Stage
Ib-IIIa NSCLC
|
Placebo
or
Imfinzi
|
FPCD
Q1
2015
First
data anticipated
2021
|
Recruitment
ongoing
|
Phase
III
PACIFIC-2
|
Unresectable,
Stage III NSCLC
|
Concurrent
CRT concurrent with
placebo
or
Imfinzi, followed
by
placebo or
Imfinzi
|
FPCD
Q2
2018
First
data anticipated
H2
2020
|
Recruitment
ongoing
|
Phase
III
PACIFIC-4
|
Unresectable,
Stage I-II NSCLC
|
Stereotactic
body
radiation
therapy
followed
by
placebo or
Imfinzi
|
FPCD
Q2
2019
First
data anticipated
2021+
|
Recruitment
ongoing
|
Phase
III
PACIFIC-5
|
Unresectable,
Stage III NSCLC
(predominantly
Asia)
|
Concurrent
or sequential CRT,
followed
by
placebo
or
Imfinzi
|
FPCD
Q1
2019
First
data anticipated
2021
|
Recruitment
ongoing
|
Phase
III
ADRIATIC
|
Limited-disease
stage SCLC
|
Concurrent
CRT,
followed
by
placebo
or
Imfinzi or Imfinzi + treme
|
FPCD
Q4
2018
First
data anticipated
2021
|
Recruitment
ongoing
|
Phase
III
PEARL
|
Stage
IV, 1st-line NSCLC (Asia)
|
SoC
chemotherapy or Imfinzi
|
FPCD
Q1
2017
LPCD
Q1
2019
First
data anticipated
2021
|
Recruitment
completed
|
Phase
III
POSEIDON
|
Stage
IV, 1st-line NSCLC
|
SoC
chemotherapy or SoC + Imfinzi or SoC + Imfinzi + treme
|
FPCD
Q2
2017
LPCD
Q3
2018
First
data anticipated
Q4
2019
|
Recruitment
completed
|
Phase
III
CASPIAN
|
Extensive-disease
stage SCLC
|
SoC
chemotherapy or SoC + Imfinzi or SoC + Imfinzi + treme
|
FPCD
Q1
2017
LPCD
Q2
2018
|
OS
primary endpoint met for Imfinzimonotherapy arm
|
Trial
|
Population
|
Design
|
Timeline
|
Status
|
Phase
III
POTOMAC
|
Non-muscle
invasive bladder cancer
|
SoC BCG[44] or
SoC BCG + Imfinzi
|
FPCD
Q3
2018
First
data
anticipated
2021+
|
Recruitment
ongoing
|
Phase
III
NIAGARA
|
Muscle-invasive
bladder cancer
|
Neo-adjuvant
cisplatin and gemcitabine SoC chemotherapy or SoC
+ Imfinzi, followed by
adjuvant placebo or Imfinzi
|
FPCD
Q4
2018
First
data
anticipated
2021+
|
Recruitment
ongoing
|
Phase
III
EMERALD-1
|
Locoregional
hepatocellular carcinoma (liver cancer)
|
TACE[45] followed
by placebo or TACE + Imfinzi, followed by Imfinzi+
bevacizumab
or
TACE
+ Imfinzi
followed
by Imfinzi
|
FPCD
Q1
2019
First
data
anticipated
2021
|
Recruitment
ongoing
|
Phase
III
EMERALD-2
|
Locoregional
hepatocellular carcinoma at high risk of recurrence after surgery
or radiofrequency ablation
|
Adjuvant Imfinzi or Imfinzi +
bevacizumab
|
FPCD
Q2
2019
First
data anticipated
2021+
|
Recruitment
ongoing
|
Phase
III
CALLA
|
Locally-advanced
cervical cancer
|
CRT or
CRT + Imfinzi,
followed by placebo or Imfinzi
|
FPCD
Q1
2019
First
data anticipated
2021+
|
Recruitment
ongoing
|
Phase
III
DANUBE
|
Stage
IV, 1st-line cisplatin chemotherapy- eligible/ineligible bladder
cancer
|
SoC
chemotherapy or Imfinzi or Imfinzi+ treme
|
FPCD
Q4
2015
LPCD
Q1
2017
First
data
anticipated
H1
2020
|
Recruitment
completed
|
Phase
III
NILE
|
Stage
IV, 1st-line cisplatin chemotherapy- eligible bladder
cancer
|
SoC
chemotherapy or SoC + Imfinzi or SoC + Imfinzi + treme
|
FPCD
Q4
2018
First
data anticipated
2021
|
Recruitment
ongoing
|
Phase
III
KESTREL
|
Stage
IV, 1st-line HNSCC
|
SoC
or Imfinzi or Imfinzi + treme
|
FPCD
Q4
2015
LPCD
Q1
2017
First
data
anticipated
H1
2020
|
Recruitment
completed
|
Phase
III
HIMALAYA
|
Stage
IV, 1st-line unresectable hepatocellular carcinoma
|
Sorafenib
or Imfinzior Imfinzi + treme
|
FPCD
Q4
2017
LPCD
Q3
2019
First
data
anticipated
H2
2020
|
Recruitment
completed
|
Phase
III
TOPAZ-1
|
Stage
IV, 1st-line biliary-tract cancer
|
Gemcitabine
and cisplatin SoC chemotherapy or SoC + Imfinzi
|
FPCD
Q2
2019
First
data anticipated
2021
|
Recruitment
ongoing
|
Trial
|
Population
|
Design
|
Timeline
|
Status
|
Phase
III
OlympiA
|
Adjuvant
BRCAm breast cancer
|
SoC
placebo or Lynparza
|
FPCD
Q2
2014
LPCD
Q2
2019
First
data anticipated
2021
|
Recruitment
completed
|
Phase
III
PROfound
|
Metastatic
castration-resistant 2nd-line+ HRRm prostate cancer
|
SoC
(abiraterone or enzalutamide) or Lynparza
|
FPCD
Q2
2017
LPCD
Q4
2018
|
Primary
endpoint met
|
Phase
III
PAOLA-1[46]
|
Stage
IV, 1st-line
ovarian
cancer
|
Bevacizumab
maintenance or
bevacizumab
+
Lynparzamaintenance
|
FPCD
Q2
2015
LPCD Q2
2018
|
Primary
endpoint met
|
Phase
III
GY004[47]
|
Recurrent
platinum-sensitive ovarian cancer
|
SoC
chemotherapy or cediranib or cediranib + Lynparza
|
FPCD
Q1
2016
First
data
anticipated
H1
2020
|
Recruitment
ongoing
|
Phase
II/III
GY00547
|
Recurrent
platinum-resistant/refractory ovarian cancer
|
SoC
chemotherapy or cediranib or cediranib + Lynparza
|
FPCD
Q2
2016
(Phase
II)
FPCD
Q1
2019
(Phase
III)
First
data
anticipated
2021+
|
Recruitment
ongoing (Phase III component)
|
Phase
III
DuO-O
|
Stage
IV, 1st-line
ovarian
cancer
|
Chemotherapy
+
bevacizumab
or
chemotherapy
+
bevacizumab
+
Imfinzi +/-
Lynparzamaintenance
|
FPCD
Q1 2019
First
data
anticipated
2021+
|
Recruitment
ongoing
|
Phase
II
MEDIOLA
|
Advanced,
2nd-line
gBRCAm[48]ovarian
cancer
Stage
IV, 1st to 3rd-line
gBRCAm,
HER2-
negative
breast cancer
Stage
IV, 2nd-line SCLC
Stage
IV, 2nd-line
gastric
cancer
|
Lynparza + Imfinzi
|
FPCD
Q2
2016
LPCD
Q1
2019
(all
except one cohort)
|
Recruitment
ongoing
in one expansion cohort
Initial
data from lung, breast, prostate and ovarian-cancer cohorts
presented in 2017 and 2018
|
Phase
II
LYNK-002
|
HRRm
advanced solid tumours
|
Lynparza
|
FPCD
Q1
2019
|
Recruitment
ongoing
|
Phase
II
VIOLETTE
|
Stage
IV, advanced, triple-negative breast cancer:
-HRRm[49](BRCA)
-HRRm
(non-BRCA)
-Non-HRRm
|
Lynparza
Lynparza + ATR
(AZD6738)
|
FPCD
Q2
2018
First
data
anticipated
2021
|
Recruitment
ongoing
|
Phase
III
PROpel
|
Stage
IV, advanced, castration-resistant prostate cancer
|
Abiraterone
or
abiraterone
+
Lynparza
|
FPCD
Q4
2018
First
data
anticipated
2021
|
Recruitment
ongoing
|
Phase
II
BAYOU
|
Stage
IV, 1st-line cis-platinum chemotherapy-ineligible
urothelial
bladder
cancer
|
Imfinzi or
Imfinzi + Lynparza
|
FPCD
Q1
2018
First
data
anticipated
H1
2020
|
Recruitment
ongoing
|
Phase
II
ORION
|
Stage
IV, 1st-line
NSCLC
|
SoC
chemotherapy + Imfinzi, followed by Imfinzi or Imfinzi+ Lynparza
maintenance
|
FPCD
Q1
2019
First
data anticipated
2021+
|
Recruitment
ongoing
|
Trial
|
Population
|
Design
|
Timeline
|
Status
|
Phase
II
DESTINY-Breast01
|
Stage
IV, HER2-positive (IHC 3+) breast cancer post trastuzumab
emtansine
|
Trastuzumab
deruxtecan
|
FPCD
Q3
2017
LPCD
Q3
2018
|
Data
read out
Q2
2019
Breakthrough
Therapy Designation (US) status awarded
|
Phase
III
DESTINY-Breast02
|
Stage
IV, HER2-positive (IHC 3+) breast cancer post trastuzumab
emtansine
|
SoC or
trastuzumab deruxtecan
|
FPCD
Q3
2018
First
data anticipated 2021
|
Recruitment ongoing
|
Phase
III
DESTINY-Breast03
|
Stage
IV, HER2-positive (IHC 3+) breast cancer
|
Trastuzumab
emtansine or trastuzumab deruxtecan
|
FPCD Q3
2018
First
data anticipated
2021
|
Recruitment ongoing
|
Phase
III
DESTINY-Breast04
|
Stage
IV, HER2-low (IHC 1+/2+) breast cancer
|
SoC or
trastuzumab deruxtecan
|
FPCD
Q4
2018
First
data anticipated
2021
|
Recruitment ongoing
|
Phase
II
DESTINY-Gastric01
|
Stage
IV, HER2-positive (IHC 3+) gastric cancer
|
SoC or
trastuzumab deruxtecan
|
FPCD Q4
2017
LPCD Q2
2019
First
data anticipated
H1
2020
|
Recruitment completed
|
Trial
|
Population
|
Design
|
Primary endpoint(s)
|
Timeline
|
Status
|
Farxiga
|
|
||||
Phase
III
DECLARE
|
c.17,000[50]patients
with T2D
|
Arm 1: Farxiga10mg QD[51] +
SoC QD
Arm 2:
placebo + SoC for T2D
|
Superiority for MACE[52] or
superiority for the composite endpoint of CV death or
hHF[53]
|
FPCD
Q2
2013
|
Primary
safety endpoint met
One of
two primary efficacy endpoints met
|
Phase
III
DAPA-HF
|
c.4,500
patients with HF and reduced ejection fraction, with and without
T2D
|
Arm
1: Farxiga10mg or 5 mg
QD + SoC
Arm 2:
placebo + SoC
|
Time to
first occurrence of CV death or hHF or an urgent HF
visit
|
FPCD
Q1
2017
LPCD
Q3
2018
|
Data
read out Q3 2019
Primary
endpoint
met
Fast
Track designation (US)
|
Phase
III
DELIVER
|
c.4,700
patients with HF and preserved ejection fraction, with and without
T2D
|
Arm
1: Farxiga10mg
QD
Arm 2:
placebo
|
Time to
first occurrence of CV death or worsening HF
|
FPCD
Q3
2018
First
data anticipated 2021+
|
Recruitment
ongoing
Fast
Track designation (US)
|
Phase
III
DAPA-CKD
|
c.4,000
patients with CKD, with and without T2D
|
Arm
1: Farxiga10mg or 5mg
QD
Arm 2:
placebo
|
Time to first occurrence of ≥ 50% sustained decline in eGFR
or reaching ESRD[54] or
CV death or renal death
|
FPCD
Q1
2017
LPCD
Q1
2019
First
data anticipated 2021
|
Recruitment
completed
Fast
Track designation (US)
|
Brilinta
|
|
||||
Phase
III THEMIS
|
c.19,000 patients with T2D and CAD without a history of
MI[55] or
stroke
|
Arm 1: Brilinta60mg BID[56]
Arm 2:
placebo BID on a background of acetylsalicylic acid if not
contra-indicated or not tolerated
|
Composite
of CV death, non-fatal MI and non-fatal stroke
|
FPCD
Q1
2014
LPCD
Q2
2016
|
Primary
endpoint met
|
Phase
III
THALES
|
c.11,000
patients with acute ischaemic stroke or transient ischaemic
attack
|
Arm
1: Brilinta90mg
BID
Arm 2:
placebo BID on a background of acetylsalicylic acid if not
contra-indicated or not tolerated
|
Prevention
of the composite of subsequent stroke and death at 30
days
|
FPCD
Q1
2018
First
data anticipated
H1
2020
|
Recruitment
ongoing
|
Epanova
|
|
||||
Phase
III
STRENGTH
|
c.13,000
patients with mixed dyslipidaemia/
hypertriglycerid-aemia
|
Arm
1: Epanova 4g QD
+ statin
Arm
2: placebo (corn oil) + statin
|
Time to
first occurrence of CV death, non-fatal MI or non-fatal
stroke
|
FPCD Q4
2014
LPCD Q2
2017
First
data anticipated
H2
2020
|
Recruitment
completed
|
Trial
|
Population
|
Design
|
Primary endpoint(s)
|
Timeline
|
Status
|
Phase
IIIb ANDHI
|
Severe
eosinophilic asthma on SoC
|
Fasenra 30mg
Q8W[57]SC[58]
Placebo
SC
24-week
trial
|
Annual
asthma exacerbation rate
|
FPCD
Q3
2017
LPCD
Q1
2019
Data
anticipated
Q4
2019
|
Recruitment
completed
|
Phase
IIIb PONENTE
|
Asthmatics (aged 18 years or older) receiving high-dose ICS plus
LABA and chronic OCS[59] with
or without additional asthma controller(s)
|
Fasenra 30mg Q8W SC
38-week
trial
|
Reduction
of OCS dose
|
FPCD
Q3
2018
LPCD
Q3
2019
Data
anticipated
H2
2020
|
Recruitment
completed
|
Phase
III MELTEMI
|
Asthmatic
adults (aged 18-75 years) on ICS plus LABA2 agonist
|
Fasenra 30mg Q4W SC
Fasenra 30mg Q8W SC
|
Safety
and tolerability
|
FPCD
Q2
2016
LPCD
Q1
2017
Data
anticipated
H2
2020
|
Recruitment
completed
|
Phase
III OSTRO
|
Patients
(aged 18-75 years) with severe bilateral nasal polyposis;
symptomatic, despite SoC
|
Fasenra 30mg Q8W SC
Placebo
SC
56-week
trial
|
Nasal-polyposis
burden and reported nasal blockage
|
FPCD
Q1
2018
LPCD
Q2
2019
Data
anticipated
H2
2020
|
Recruitment
completed
|
Phase
III MIRACLE
|
Severe
eosinophilic asthma (aged 12-75 years) despite background
controller medication, medium dose and high dose ICS plus LABA
± chronic OCS (CN)
|
Fasenra 30mg Q8W SC
Placebo
SC
56-week
trial
|
Annual
asthma-exacerbation rate
|
FPCD
Q3
2017
Data
anticipated 2021+
|
Recruitment
ongoing
|
Phase
III RESOLUTE
|
Patients with moderate
to very severe COPD with a history of frequent COPD exacerbations
and elevated peripheral blood eosinophils
|
Fasenra 100mg Q8W SC
Placebo
SC
56-week
trial
|
Annualised
rate of moderate or severe COPD exacerbations
|
FPCD
Q4
2019
Data
anticipated 2021+
|
Recruitment
ongoing
|
Phase
III
MANDARA
|
EGPA
|
Fasenra 30mg Q4W
Mepolizumab
3x100mg Q4W
52-week
trial with open-label extension
|
Proportion of patients who achieve remission, defined as a
score[60] =0
and an OCS dose ≤4 mg/day at weeks 36 and
48
|
FPCD
Q4
2019
Data
anticipated
2021+
|
Recruitment
ongoing
Orphan
Drug Designation (US)
|
Phase
III
NATRON
|
HES
|
Fasenra 30mg Q4W
Placebo
SC
24-week
trial with open-label extension
|
Time to
HES worsening flare or any cytotoxic and/or immuno-suppressive
therapy increase or hospitalisation
|
FPCD
Q4
2019
Data
anticipated 2021+
|
Recruitment
ongoing
Orphan
Drug Designation (US)
|
Phase
III
MESSINA
|
Eosinophilic
oesophagitis
|
Fasenra 30mg SC Q4W
Placebo
SC
24-week
trial with open-label extension
|
Proportion
of patients with a histologic response
Changes from baseline in dysphagia PRO[61]
|
Data
anticipated 2021+
|
Initiating
Orphan
Drug Designation (US)
|
Trial
|
Population
|
Design
|
Primary endpoint(s)
|
Timeline
|
Status
|
Phase II
MUSE
|
Moderate to severely-active SLE patients on background
SoC
|
300mg i.v.[62]anifrolumab
Q4W
1,000mg i.v. anifrolumab Q4W
Placebo i.v. Q4W
52-week trial
|
Response in SLE responder index, with sustained reduction of OCSs
at six months
|
FPCD
Q1 2012
LPCD
Q1 2014
|
Data read out Q2 2015
Primary endpoint met
Fast Track designation (US)
|
Phase III
TULIP 1
|
Moderate to severely-active SLE patients on background
SoC
|
300mg i.v. anifrolumab Q4W
150mg i.v. anifrolumab Q4W
Placebo i.v. Q4W
52-week trial
|
Response in SLE
responder index at week 52
|
FPCD
Q3 2015
LPCD
Q3 2017
|
Data read out Q3 2018
Primary endpoint not met
Fast Track designation (US)
|
Phase III
TULIP 2
|
Moderate to severely-active SLE patients on background
SoC
|
300mg i.v. anifrolumab Q4W
Placebo i.v. Q4W
52-week trial
|
Response in BICLA at week 52
|
FPCD
Q3 2015
LPCD
Q3 2017
|
Data read out Q3 2019
Primary endpoint met
Fast Track designation (US)
|
Phase III
TULIP LTE[63]
|
Moderate to severely active SLE patients on background SoC who have
completed a Phase III anifrolumab trial
|
300mg i.v. anifrolumab Q4W
Placebo i.v. Q4W
152-week
trial
|
Long-term safety
|
FPCD
Q2 2016
LPCD
Q4 2018
Data anticipated
2021+
|
Recruitment completed
Fast Track designation (US)
|
Phase II
NCT02962960
|
SLE patients with high interferon type I status and active skin
manifestations
|
150mg SC every other week
300mg SC every other week
Placebo SC every other week
52-week trial
|
PK[64]/PD[65],
safety, tolerability
|
FPCD
Q1 2017
LPCD
Q4 2017
|
Trial
completed
Data
read out Q1 2018
|
Phase II
TULIP-LN1
|
Patients with active, proliferative
LN[66]
|
900 mg i.v. Q4W for 12 weeks, then 300mg i.v. anifrolumab Q4W for
36 weeks
300mg i.v. anifrolumab Q4W
Placebo i.v. Q4W
52-week
trial
|
Response in proteinuria at week 52
|
FPCD
Q4 2015
LPCD
Q4 2018
Data anticipated
2021
|
Recruitment completed
|
|
2019
|
2018
|
For the nine months ended 30 September
|
$m
|
$m
|
Product Sales
|
17,315
|
15,281
|
Collaboration Revenue
|
405
|
392
|
|
|
|
Total Revenue
|
17,720
|
15,673
|
Cost of sales
|
(3,543)
|
(3,299)
|
|
|
|
Gross Profit
|
14,177
|
12,374
|
Distribution costs
|
(247)
|
(238)
|
Research and development expense
|
(3,968)
|
(3,920)
|
Selling, general and administrative costs
|
(8,656)
|
(7,431)
|
Other operating income and expense
|
1,041
|
1,525
|
|
|
|
Operating profit
|
2,347
|
2,310
|
Finance income
|
133
|
112
|
Finance expense
|
(1,081)
|
(1,082)
|
Share of after-tax losses in associates and joint
ventures
|
(91)
|
(77)
|
|
|
|
Profit before tax
|
1,308
|
1,263
|
Taxation
|
(358)
|
(222)
|
|
|
|
Profit for the period
|
950
|
1,041
|
|
|
|
Other comprehensive income
|
|
|
Items that will not be reclassified to profit or loss
|
|
|
Remeasurement of the defined benefit pension liability
|
(151)
|
138
|
Net (losses)/gains on equity investments measured at fair value
through other comprehensive income
|
(136)
|
159
|
Fair-value movements related to own credit risk on bonds designated
as fair-value through profit or loss
|
(1)
|
3
|
Tax on items that will not be reclassified to profit or
loss
|
21
|
(65)
|
|
(267)
|
235
|
|
|
|
Items that may be reclassified subsequently to profit or
loss
|
|
|
Foreign exchange arising on consolidation
|
(385)
|
(351)
|
Foreign exchange arising on designating borrowings in net
investment hedges
|
(491)
|
(449)
|
Fair-value movements on cash flow hedges
|
(156)
|
5
|
Fair-value movements on cash flow hedges transferred to profit or
loss
|
109
|
72
|
Fair-value movements on derivatives designated in net investment
hedges
|
35
|
7
|
Costs of hedging
|
(35)
|
(36)
|
Tax on items that may be reclassified subsequently to profit or
loss
|
62
|
39
|
|
(861)
|
(713)
|
|
|
|
Other comprehensive loss for the period, net of tax
|
(1,128)
|
(478)
|
Total comprehensive (loss)/income for the period
|
(178)
|
563
|
|
|
|
Profit attributable to:
|
|
|
Owners of the Parent
|
1,022
|
1,121
|
Non-controlling interests
|
(72)
|
(80)
|
|
950
|
1,041
|
|
|
|
Total comprehensive income attributable to:
|
|
|
Owners of the Parent
|
(107)
|
644
|
Non-controlling interests
|
(71)
|
(81)
|
|
(178)
|
563
|
|
|
|
Basic earnings per $0.25 Ordinary Share
|
$0.79
|
$0.88
|
Diluted earnings per $0.25 Ordinary Share
|
$0.79
|
$0.88
|
Weighted average number of Ordinary Shares in issue
(millions)
|
1,297
|
1,267
|
Diluted weighted average number of Ordinary Shares in issue
(millions)
|
1,297
|
1,267
|
|
2019
|
2018
|
For the quarter ended 30 September
|
$m
|
$m
|
Product Sales
|
6,132
|
5,266
|
Collaboration Revenue
|
274
|
74
|
|
|
|
Total Revenue
|
6,406
|
5,340
|
Cost of sales
|
(1,351)
|
(1,153)
|
|
|
|
Gross Profit
|
5,055
|
4,187
|
Distribution costs
|
(88)
|
(73)
|
Research and development expense
|
(1,346)
|
(1,279)
|
Selling, general and administrative costs
|
(3,199)
|
(2,423)
|
Other operating income and expense
|
335
|
439
|
|
|
|
Operating profit
|
757
|
851
|
Finance income
|
37
|
34
|
Finance expense
|
(353)
|
(364)
|
Share of after-tax losses in associates and joint
ventures
|
(32)
|
(44)
|
|
|
|
Profit before tax
|
409
|
477
|
Taxation
|
(129)
|
(71)
|
|
|
|
Profit for the period
|
280
|
406
|
|
|
|
Other comprehensive income
|
|
|
Items that will not be reclassified to profit or loss
|
|
|
Remeasurement of the defined benefit pension liability
|
96
|
(49)
|
Net (losses)/gains on equity investments measured at fair value
through other comprehensive income
|
(82)
|
3
|
Fair-value movements related to own credit risk on bonds designated
as fair value through profit or loss
|
1
|
5
|
Tax on items that will not be reclassified to profit or
loss
|
4
|
2
|
|
19
|
(39)
|
|
|
|
Items that may be reclassified subsequently to profit or
loss
|
|
|
Foreign exchange arising on consolidation
|
(299)
|
(67)
|
Foreign exchange arising on designating borrowings in net
investment hedges
|
(305)
|
67
|
Fair-value movements on cash flow hedges
|
(113)
|
(14)
|
Fair-value movements on cash flow hedges transferred to profit or
loss
|
95
|
3
|
Fair-value movements on derivatives designated in net investment
hedges
|
44
|
11
|
Costs of hedging
|
(38)
|
(3)
|
Tax on items that may be reclassified subsequently to profit or
loss
|
42
|
(16)
|
|
(574)
|
(19)
|
|
|
|
Other comprehensive loss for the period, net of tax
|
(555)
|
(58)
|
Total comprehensive (loss)/income for the period
|
(275)
|
348
|
|
|
|
Profit attributable to:
|
|
|
Owners of the Parent
|
299
|
431
|
Non-controlling interests
|
(19)
|
(25)
|
|
280
|
406
|
|
|
|
Total comprehensive income attributable to:
|
|
|
Owners of the Parent
|
(257)
|
374
|
Non-controlling interests
|
(18)
|
(26)
|
|
(275)
|
348
|
|
|
|
Basic earnings per $0.25 Ordinary Share
|
$0.23
|
$0.34
|
Diluted earnings per $0.25 Ordinary Share
|
$0.23
|
$0.34
|
Weighted average number of Ordinary Shares in issue
(millions)
|
1,312
|
1,267
|
Diluted weighted average number of Ordinary Shares in issue
(millions)
|
1,312
|
1,267
|
|
At 30 Sep 2019
|
At 31 Dec 2018
|
At 30 Sep 2018
|
|
$m
|
$m
|
$m
|
Assets
|
|
|
|
Non-current assets
|
|
|
|
Property, plant and equipment
|
7,317
|
7,421
|
7,591
|
Right-of-use assets
|
690
|
-
|
-
|
Goodwill
|
11,595
|
11,707
|
11,729
|
Intangible assets
|
21,454
|
21,959
|
24,418
|
Investments in associates and joint ventures
|
43
|
89
|
110
|
Other investments
|
1,293
|
833
|
1,124
|
Derivative financial instruments
|
56
|
157
|
449
|
Other receivables
|
384
|
515
|
708
|
Deferred tax assets
|
2,554
|
2,379
|
2,206
|
|
45,386
|
45,060
|
48,335
|
Current assets
|
|
|
|
Inventories
|
3,129
|
2,890
|
3,027
|
Trade and other receivables
|
5,279
|
5,574
|
5,509
|
Other investments
|
813
|
849
|
808
|
Derivative financial instruments
|
9
|
258
|
34
|
Intangible assets
|
95
|
-
|
-
|
Income tax receivable
|
228
|
207
|
310
|
Cash and cash equivalents
|
3,967
|
4,831
|
3,420
|
Assets held for sale
|
-
|
982
|
-
|
|
13,520
|
15,591
|
13,108
|
Total assets
|
58,906
|
60,651
|
61,443
|
|
|
|
|
Liabilities
|
|
|
|
Current liabilities
|
|
|
|
Interest-bearing loans and borrowings
|
(228)
|
(1,754)
|
(2,491)
|
Lease liabilities
|
(349)
|
-
|
-
|
Trade and other payables
|
(12,538)
|
(12,841)
|
(10,992)
|
Derivative financial instruments
|
(26)
|
(27)
|
(33)
|
Provisions
|
(401)
|
(506)
|
(508)
|
Income tax payable
|
(1,234)
|
(1,164)
|
(1,224)
|
|
(14,776)
|
(16,292)
|
(15,248)
|
Non-current liabilities
|
|
|
|
Interest-bearing loans and borrowings
|
(17,218)
|
(17,359)
|
(18,422)
|
Lease liabilities
|
(363)
|
-
|
-
|
Derivative financial instruments
|
(55)
|
(4)
|
(2)
|
Deferred tax liabilities
|
(2,595)
|
(3,286)
|
(3,685)
|
Retirement benefit obligations
|
(2,392)
|
(2,511)
|
(2,267)
|
Provisions
|
(990)
|
(385)
|
(393)
|
Other payables
|
(6,848)
|
(6,770)
|
(7,889)
|
|
(30,461)
|
(30,315)
|
(32,658)
|
Total liabilities
|
(45,237)
|
(46,607)
|
(47,906)
|
Net assets
|
13,669
|
14,044
|
13,537
|
Equity
|
|
|
|
Capital and reserves attributable to equity holders of the
Parent
|
|
|
|
Share capital
|
328
|
317
|
317
|
Share premium account
|
7,919
|
4,427
|
4,417
|
Other reserves
|
2,052
|
2,041
|
2,040
|
Retained earnings
|
1,865
|
5,683
|
5,162
|
|
12,164
|
12,468
|
11,936
|
Non-controlling interests
|
1,505
|
1,576
|
1,601
|
Total equity
|
13,669
|
14,044
|
13,537
|
|
Share capital
|
Share premium account
|
Other reserves
|
Retained earnings
|
Total attributable to owners of the parent
|
Non-controlling interests
|
Total equity
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
At 1 Jan 2018
|
317
|
4,393
|
2,029
|
8,221
|
14,960
|
1,682
|
16,642
|
|
|
|
|
|
|
|
|
Adoption of new accounting standards
|
-
|
-
|
-
|
(91)
|
(91)
|
-
|
(91)
|
Profit for the period
|
-
|
-
|
-
|
1,121
|
1,121
|
(80)
|
1,041
|
Other comprehensive loss
|
-
|
-
|
-
|
(477)
|
(477)
|
(1)
|
(478)
|
Transfer to other reserves
|
-
|
-
|
11
|
(11)
|
-
|
-
|
-
|
Transactions with owners:
|
|
|
|
|
|
|
|
Dividends
|
-
|
-
|
-
|
(3,542)
|
(3,542)
|
-
|
(3,542)
|
Issue of Ordinary Shares
|
-
|
24
|
-
|
-
|
24
|
-
|
24
|
Share-based payments change for the period
|
-
|
-
|
-
|
151
|
151
|
-
|
151
|
Settlement of share plan awards
|
-
|
-
|
-
|
(210)
|
(210)
|
-
|
(210)
|
|
|
|
|
|
|
|
|
Net movement
|
-
|
24
|
11
|
(3,059)
|
(3,024)
|
(81)
|
(3,105)
|
|
|
|
|
|
|
|
|
At 30 Sep 2018
|
317
|
4,417
|
2,040
|
5,162
|
11,936
|
1,601
|
13,537
|
|
|
|
|
|
|
|
|
At 1 Jan 2019
|
317
|
4,427
|
2,041
|
5,683
|
12,468
|
1,576
|
14,044
|
|
|
|
|
|
|
|
|
Adoption of new accounting standards[67]
|
-
|
-
|
-
|
54
|
54
|
-
|
54
|
Profit for the period
|
-
|
-
|
-
|
1,022
|
1,022
|
(72)
|
950
|
Other comprehensive loss
|
-
|
-
|
-
|
(1,129)
|
(1,129)
|
1
|
(1,128)
|
Transfer to other reserves
|
-
|
-
|
11
|
(11)
|
-
|
-
|
-
|
Transactions with owners:
|
|
|
|
|
|
|
|
Dividends
|
-
|
-
|
-
|
(3,583)
|
(3,583)
|
-
|
(3,583)
|
Issue of Ordinary Shares[68]
|
11
|
3,492
|
-
|
-
|
3,503
|
-
|
3,503
|
Share-based payments for the period
|
-
|
-
|
-
|
154
|
154
|
-
|
154
|
Settlement of share awards
|
-
|
-
|
-
|
(325)
|
(325)
|
-
|
(325)
|
|
|
|
|
|
|
|
|
Net movements
|
11
|
3,492
|
11
|
(3,818)
|
(304)
|
(71)
|
(375)
|
At 30 Sep 2019
|
328
|
7,919
|
2,052
|
1,865
|
12,164
|
1,505
|
13,669
|
|
2019
|
2018
|
For the nine months ended 30 September
|
$m
|
$m
|
Cash flows from operating activities
|
|
|
Profit before tax
|
1,308
|
1,263
|
Finance income and expense
|
948
|
970
|
Share of after-tax losses of associates and joint
ventures
|
91
|
77
|
Depreciation, amortisation and impairment
|
2,119
|
2,091
|
Increase in working capital and short-term provisions
|
(812)
|
(1,741)
|
Gains on disposal of intangible assets
|
(833)
|
(975)
|
Fair value movements on contingent consideration arising from
business combinations
|
(13)
|
(88)
|
Non-cash and other movements
|
326
|
(340)
|
|
|
|
Cash generated from operations
|
3,134
|
1,257
|
Interest paid
|
(575)
|
(457)
|
Tax paid
|
(965)
|
(406)
|
|
|
|
Net cash inflow from operating activities
|
1,594
|
394
|
|
|
|
Cash flows from investing activities
|
|
|
Payment of contingent consideration from business
combinations
|
(487)
|
(247)
|
Purchase of property, plant and equipment
|
(659)
|
(728)
|
Disposal of property, plant and equipment
|
31
|
12
|
Purchase of intangible assets
|
(1,416)
|
(234)
|
Disposal of intangible assets
|
1,400
|
842
|
Movement in profit-participation liability[69]
|
150
|
-
|
Purchase of non-current asset investments
|
(6)
|
(46)
|
Disposal of non-current asset investments
|
18
|
24
|
Movement in short-term investments and fixed deposits
|
196
|
434
|
Payments to associates and joint ventures
|
(49)
|
(172)
|
Interest received
|
107
|
151
|
|
|
|
Net cash (outflow)/inflow from investing activities
|
(715)
|
36
|
|
|
|
Net cash inflow before financing activities
|
879
|
430
|
|
|
|
Cash flows from financing activities
|
|
|
Proceeds from issue of share capital
|
3,503
|
24
|
Issue of loans
|
500
|
2,974
|
Repayment of loans
|
(1,500)
|
-
|
Dividends paid
|
(3,592)
|
(3,484)
|
Hedge contracts relating to dividend payments
|
4
|
(67)
|
Repayment of obligations under leases
|
(131)
|
-
|
Movement in short-term borrowings
|
(555)
|
241
|
|
|
|
Net cash outflow from financing activities
|
(1,771)
|
(312)
|
|
|
|
Net (decrease)/increase in cash and cash equivalents in the
period
|
(892)
|
118
|
Cash and cash equivalents at the beginning of the
period
|
4,671
|
3,172
|
Exchange rate effects
|
-
|
(28)
|
|
|
|
Cash and cash equivalents at the end of the period
|
3,779
|
3,262
|
|
|
|
Cash and cash equivalents consist of:
|
|
|
Cash and cash equivalents
|
3,967
|
3,420
|
Overdrafts
|
(188)
|
(158)
|
|
3,779
|
3,262
|
|
YTD 2019
|
YTD 2018
|
Q3 2019
|
Q3 2018
|
|
$m
|
$m
|
$m
|
$m
|
Cost of sales
|
122
|
77
|
70
|
22
|
Research and development expense
|
82
|
95
|
18
|
37
|
Selling, general and administrative costs
|
147
|
110
|
37
|
26
|
Other operating income and expense
|
-
|
(11)
|
-
|
(1)
|
Total
|
351
|
271
|
125
|
84
|
|
At 1 Jan 2019
|
Adoption of new
accounting standards[70]
|
Cash Flow
|
Non-cash & Other
|
Exchange Movements
|
At 30 Sep 2019
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
Non-current instalments of loans
|
(17,359)
|
-
|
-
|
(15)
|
156
|
(17,218)
|
Non-current instalments of leases
|
-
|
(557)
|
-
|
189
|
5
|
(363)
|
|
|
|
|
|
|
|
Total long-term debt
|
(17,359)
|
(557)
|
-
|
174
|
161
|
(17,581)
|
|
|
|
|
|
|
|
Current instalments of loans
|
(999)
|
-
|
1,000
|
(1)
|
-
|
-
|
Current instalments of leases
|
-
|
(163)
|
149
|
(338)
|
3
|
(349)
|
Commercial paper
|
(211)
|
-
|
211
|
-
|
-
|
-
|
Bank collateral
|
(384)
|
-
|
347
|
-
|
-
|
(37)
|
Other short-term borrowings excluding overdrafts
|
-
|
-
|
(3)
|
-
|
-
|
(3)
|
Overdraft
|
(160)
|
-
|
(34)
|
-
|
6
|
(188)
|
|
|
|
|
|
|
|
Total current debt
|
(1,754)
|
(163)
|
1,670
|
(339)
|
9
|
(577)
|
|
|
|
|
|
|
|
Gross borrowings
|
(19,113)
|
(720)
|
1,670
|
(165)
|
170
|
(18,158)
|
|
|
|
|
|
|
|
Net derivative financial instruments
|
384
|
-
|
(214)
|
(186)
|
-
|
(16)
|
|
|
|
|
|
|
|
Net borrowings
|
(18,729)
|
(720)
|
1,456
|
(351)
|
170
|
(18,174)
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
4,831
|
-
|
(858)
|
-
|
(6)
|
3,967
|
Other investments - current
|
849
|
-
|
14
|
(47)
|
(3)
|
813
|
Other investments - non-current
|
46
|
-
|
-
|
50
|
-
|
96
|
Cash and investments
|
5,726
|
-
|
(844)
|
3
|
(9)
|
4,876
|
|
|
|
|
|
|
|
Net debt
|
(13,003)
|
(720)
|
612
|
(348)
|
161
|
(13,298)
|
|
Diabetes Alliance
2019
|
Other
2019
|
Total
2019
|
Total
2018
|
|
$m
|
$m
|
$m
|
$m
|
At 1 January
|
3,983
|
1,123
|
5,106
|
5,534
|
Settlements
|
(337)
|
(150)
|
(487)
|
(247)
|
Revaluations
|
-
|
(13)
|
(13)
|
38
|
Discount unwind
|
216
|
53
|
269
|
313
|
At 30 September
|
3,862
|
1,013
|
4,875
|
5,638
|
|
World
|
Emerging Markets
|
US
|
Europe
|
Established RoW
|
|||||||||
|
YTD 2019
|
Actual
|
CER
|
YTD 2019
|
Actual
|
CER
|
YTD 2019
|
Actual
|
YTD 2019
|
Actual
|
CER
|
YTD 2019
|
Actual
|
CER
|
|
$m
|
%
|
%
|
$m
|
%
|
%
|
$m
|
%
|
$m
|
%
|
%
|
$m
|
%
|
%
|
Oncology
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Tagrisso
|
2,305
|
82
|
86
|
553
|
n/m
|
n/m
|
909
|
57
|
337
|
52
|
61
|
506
|
n/m
|
n/m
|
Imfinzi
|
1,045
|
n/m
|
n/m
|
18
|
n/m
|
n/m
|
759
|
n/m
|
115
|
n/m
|
n/m
|
153
|
n/m
|
n/m
|
Lynparza
|
847
|
93
|
98
|
101
|
n/m
|
n/m
|
432
|
86
|
208
|
52
|
61
|
106
|
n/m
|
n/m
|
Iressa
|
343
|
(16)
|
(11)
|
227
|
-
|
6
|
14
|
(31)
|
61
|
(29)
|
(24)
|
42
|
(45)
|
(44)
|
Calquence
|
108
|
n/m
|
n/m
|
1
|
-
|
-
|
108
|
n/m
|
-
|
-
|
-
|
-
|
-
|
-
|
Faslodex*
|
726
|
(4)
|
(1)
|
145
|
31
|
41
|
311
|
(21)
|
168
|
(2)
|
4
|
102
|
23
|
23
|
Zoladex*
|
617
|
8
|
15
|
380
|
21
|
30
|
5
|
(16)
|
100
|
1
|
7
|
133
|
(13)
|
(11)
|
Arimidex*
|
174
|
5
|
10
|
118
|
12
|
19
|
-
|
-
|
21
|
(7)
|
(1)
|
34
|
(7)
|
(6)
|
Casodex*
|
157
|
2
|
6
|
99
|
10
|
17
|
-
|
(89)
|
12
|
(19)
|
(13)
|
46
|
(7)
|
(6)
|
Others
|
68
|
(26)
|
(24)
|
22
|
(9)
|
(5)
|
-
|
-
|
5
|
(4)
|
2
|
42
|
(34)
|
(34)
|
Total Oncology
|
6,393
|
50
|
54
|
1,665
|
42
|
51
|
2,538
|
57
|
1,027
|
34
|
42
|
1,163
|
66
|
67
|
BioPharmaceuticals: CVRM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Farxiga
|
1,124
|
13
|
17
|
339
|
40
|
50
|
396
|
(6)
|
273
|
18
|
26
|
115
|
14
|
16
|
Brilinta
|
1,153
|
22
|
26
|
348
|
50
|
59
|
500
|
22
|
262
|
2
|
9
|
43
|
(4)
|
1
|
Bydureon
|
410
|
(8)
|
(7)
|
9
|
(2)
|
2
|
340
|
(5)
|
50
|
(19)
|
(14)
|
11
|
(29)
|
(25)
|
Onglyza
|
396
|
-
|
4
|
131
|
8
|
17
|
174
|
7
|
53
|
(22)
|
(17)
|
38
|
(15)
|
(12)
|
Byetta
|
83
|
(12)
|
(10)
|
8
|
33
|
49
|
52
|
(6)
|
14
|
(35)
|
(30)
|
9
|
(21)
|
(17)
|
Other diabetes
|
36
|
33
|
35
|
1
|
(36)
|
(34)
|
28
|
21
|
7
|
n/m
|
n/m
|
1
|
-
|
-
|
Lokelma
|
6
|
-
|
-
|
-
|
-
|
-
|
6
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Crestor*
|
982
|
(9)
|
(5)
|
621
|
(2)
|
4
|
88
|
(31)
|
112
|
(30)
|
(25)
|
162
|
-
|
1
|
Seloken/Toprol-XL*
|
570
|
3
|
10
|
513
|
4
|
12
|
30
|
(9)
|
18
|
16
|
16
|
8
|
(15)
|
(11)
|
Atacand*
|
161
|
(20)
|
(16)
|
117
|
3
|
10
|
8
|
(28)
|
22
|
(65)
|
(65)
|
14
|
(4)
|
2
|
Others
|
199
|
(13)
|
(9)
|
139
|
(11)
|
(7)
|
-
|
(96)
|
46
|
(16)
|
(12)
|
15
|
(23)
|
(21)
|
BioPharmaceuticals: total CVRM
|
5,121
|
3
|
7
|
2,225
|
11
|
18
|
1,622
|
1
|
858
|
(8)
|
(3)
|
416
|
(2)
|
1
|
BioPharmaceuticals: Respiratory
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Symbicort
|
1,783
|
(7)
|
(4)
|
401
|
10
|
18
|
585
|
(11)
|
508
|
(14)
|
(8)
|
289
|
(9)
|
(7)
|
Pulmicort
|
1,053
|
17
|
23
|
845
|
23
|
29
|
89
|
10
|
60
|
(12)
|
(6)
|
60
|
-
|
1
|
Fasenra
|
498
|
n/m
|
n/m
|
4
|
-
|
-
|
343
|
n/m
|
81
|
n/m
|
n/m
|
70
|
n/m
|
n/m
|
Daliresp/Daxas
|
157
|
16
|
17
|
3
|
(22)
|
(17)
|
134
|
21
|
19
|
(4)
|
2
|
1
|
-
|
3
|
Duaklir
|
55
|
(24)
|
(20)
|
1
|
(4)
|
-
|
-
|
-
|
53
|
(24)
|
(20)
|
1
|
(38)
|
(36)
|
Tudorza/Eklira
|
50
|
(45)
|
(42)
|
1
|
(5)
|
(3)
|
1
|
(98)
|
44
|
(18)
|
(13)
|
4
|
(44)
|
(42)
|
Bevespi
|
30
|
32
|
32
|
-
|
-
|
-
|
30
|
31
|
-
|
-
|
-
|
-
|
-
|
-
|
Breztri
|
1
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
1
|
-
|
-
|
Others
|
226
|
(3)
|
2
|
164
|
85
|
96
|
2
|
(58)
|
54
|
(49)
|
(47)
|
6
|
(82)
|
(81)
|
BioPharmaceuticals: total Respiratory
|
3,854
|
9
|
13
|
1,419
|
24
|
31
|
1,183
|
15
|
819
|
(11)
|
(6)
|
433
|
(4)
|
(2)
|
Other medicines
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nexium
|
1,130
|
(14)
|
(11)
|
574
|
10
|
16
|
175
|
(30)
|
49
|
(73)
|
(71)
|
332
|
(8)
|
(7)
|
Synagis
|
295
|
(29)
|
(29)
|
-
|
-
|
-
|
36
|
(73)
|
258
|
(8)
|
(8)
|
-
|
-
|
-
|
Losec/Prilosec
|
217
|
3
|
8
|
145
|
11
|
17
|
7
|
38
|
45
|
(12)
|
(7)
|
20
|
(19)
|
(17)
|
Seroquel XR/IR
|
151
|
(51)
|
(49)
|
41
|
(61)
|
(60)
|
27
|
(71)
|
67
|
(17)
|
(13)
|
15
|
(34)
|
(33)
|
Movantik/Moventig
|
72
|
(15)
|
(15)
|
-
|
-
|
-
|
70
|
(14)
|
2
|
(11)
|
(12)
|
-
|
n/m
|
n/m
|
Others
|
83
|
(54)
|
(48)
|
4
|
(89)
|
(93)
|
29
|
23
|
44
|
(36)
|
(33)
|
5
|
(89)
|
(70)
|
Total other medicines
|
1,948
|
(22)
|
(20)
|
765
|
(4)
|
1
|
345
|
(41)
|
465
|
(30)
|
(28)
|
373
|
(19)
|
(16)
|
Total Product Sales
|
17,315
|
13
|
17
|
6,074
|
19
|
26
|
5,688
|
18
|
3,168
|
(4)
|
2
|
2,385
|
17
|
19
|
|
World
|
Emerging Markets
|
US
|
Europe
|
Established RoW
|
|||||||||
|
Q3 2019
|
Actual
|
CER
|
Q3 2019
|
Actual
|
CER
|
Q3 2019
|
Actual
|
Q3 2019
|
Actual
|
CER
|
Q3 2019
|
Actual
|
CER
|
|
$m
|
%
|
%
|
$m
|
%
|
%
|
$m
|
%
|
$m
|
%
|
%
|
$m
|
%
|
%
|
Oncology
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Tagrisso
|
891
|
76
|
78
|
224
|
n/m
|
n/m
|
350
|
47
|
125
|
51
|
56
|
192
|
n/m
|
n/m
|
Imfinzi
|
412
|
n/m
|
n/m
|
6
|
n/m
|
n/m
|
286
|
68
|
55
|
n/m
|
n/m
|
65
|
n/m
|
n/m
|
Lynparza
|
327
|
94
|
96
|
42
|
n/m
|
n/m
|
170
|
n/m
|
77
|
54
|
60
|
38
|
92
|
92
|
Iressa
|
91
|
(31)
|
(29)
|
63
|
(19)
|
(17)
|
6
|
(4)
|
15
|
(39)
|
(34)
|
8
|
(67)
|
(69)
|
Calquence
|
44
|
n/m
|
n/m
|
1
|
-
|
-
|
44
|
(89)
|
-
|
-
|
-
|
-
|
-
|
-
|
Faslodex
|
205
|
(20)
|
(19)
|
49
|
23
|
25
|
60
|
(55)
|
58
|
9
|
14
|
38
|
27
|
24
|
Zoladex
|
226
|
17
|
21
|
145
|
31
|
36
|
1
|
(65)
|
35
|
11
|
19
|
46
|
(7)
|
(7)
|
Arimidex
|
63
|
15
|
17
|
46
|
32
|
32
|
-
|
-
|
6
|
(20)
|
(4)
|
10
|
(13)
|
(12)
|
Casodex
|
52
|
3
|
5
|
34
|
11
|
14
|
-
|
n/m
|
4
|
5
|
24
|
14
|
(8)
|
(13)
|
Others
|
20
|
(27)
|
(26)
|
6
|
(27)
|
(28)
|
-
|
-
|
2
|
(11)
|
4
|
13
|
(30)
|
(29)
|
Total Oncology
|
2,334
|
46
|
48
|
617
|
45
|
49
|
917
|
40
|
377
|
44
|
51
|
423
|
67
|
63
|
BioPharmaceuticals: CVRM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Farxiga
|
398
|
12
|
14
|
133
|
56
|
59
|
126
|
(18)
|
95
|
21
|
26
|
43
|
17
|
18
|
Brilinta
|
416
|
24
|
27
|
131
|
56
|
61
|
179
|
18
|
91
|
7
|
12
|
15
|
2
|
3
|
Bydureon
|
127
|
(16)
|
(16)
|
2
|
(7)
|
(90)
|
106
|
(16)
|
16
|
(15)
|
(3)
|
3
|
(48)
|
(34)
|
Onglyza
|
127
|
(9)
|
(7)
|
44
|
10
|
18
|
54
|
(16)
|
17
|
(18)
|
(16)
|
12
|
(23)
|
(22)
|
Byetta
|
28
|
(19)
|
(18)
|
4
|
98
|
48
|
17
|
(28)
|
4
|
(27)
|
(11)
|
3
|
(10)
|
5
|
Other diabetes
|
14
|
38
|
44
|
1
|
(36)
|
(34)
|
11
|
34
|
3
|
n/m
|
n/m
|
-
|
-
|
-
|
Lokelma
|
4
|
-
|
-
|
-
|
-
|
-
|
4
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Crestor
|
337
|
(4)
|
(2)
|
214
|
3
|
7
|
34
|
(11)
|
37
|
(23)
|
(22)
|
53
|
(12)
|
(15)
|
Seloken/Toprol-XL
|
177
|
(1)
|
3
|
164
|
-
|
3
|
4
|
(41)
|
5
|
37
|
38
|
3
|
16
|
29
|
Atacand
|
55
|
(15)
|
(11)
|
41
|
8
|
12
|
2
|
88
|
7
|
(67)
|
(67)
|
5
|
9
|
27
|
Others
|
65
|
(8)
|
(6)
|
44
|
(5)
|
(8)
|
-
|
-
|
16
|
(16)
|
(2)
|
6
|
(5)
|
-
|
BioPharmaceuticals: total CVRM
|
1,749
|
3
|
6
|
777
|
16
|
19
|
537
|
(6)
|
292
|
(3)
|
2
|
143
|
(4)
|
(3)
|
BioPharmaceuticals: Respiratory
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Symbicort
|
613
|
(1)
|
1
|
138
|
12
|
18
|
203
|
(6)
|
154
|
(13)
|
(10)
|
118
|
15
|
14
|
Pulmicort
|
337
|
28
|
31
|
269
|
31
|
35
|
33
|
50
|
16
|
(13)
|
(6)
|
20
|
10
|
8
|
Fasenra
|
202
|
n/m
|
n/m
|
3
|
-
|
-
|
135
|
n/m
|
36
|
n/m
|
n/m
|
28
|
84
|
80
|
Daliresp/Daxas
|
53
|
2
|
3
|
1
|
(63)
|
(57)
|
45
|
4
|
7
|
20
|
25
|
-
|
-
|
-
|
Duaklir
|
18
|
(21)
|
(19)
|
1
|
-
|
-
|
-
|
-
|
17
|
(26)
|
(20)
|
-
|
-
|
-
|
Tudorza/Eklira
|
17
|
(4)
|
-
|
2
|
95
|
97
|
1
|
n/m
|
13
|
(17)
|
(13)
|
1
|
(27)
|
(19)
|
Bevespi
|
10
|
4
|
4
|
-
|
-
|
-
|
10
|
1
|
-
|
-
|
-
|
-
|
-
|
-
|
Breztri
|
1
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
1
|
-
|
-
|
Others
|
67
|
(5)
|
-
|
49
|
76
|
80
|
1
|
(77)
|
15
|
(52)
|
(46)
|
2
|
(75)
|
(72)
|
BioPharmaceuticals: total Respiratory
|
1,319
|
15
|
18
|
463
|
28
|
32
|
427
|
20
|
258
|
(8)
|
(3)
|
171
|
17
|
16
|
Other medicines
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nexium
|
374
|
(11)
|
(10)
|
205
|
13
|
18
|
56
|
(10)
|
17
|
(71)
|
(65)
|
96
|
(21)
|
(24)
|
Synagis
|
146
|
(11)
|
(11)
|
-
|
-
|
-
|
1
|
(83)
|
144
|
(7)
|
(7)
|
-
|
-
|
-
|
Losec/Prilosec
|
73
|
10
|
13
|
49
|
15
|
18
|
3
|
n/m
|
14
|
(9)
|
(3)
|
7
|
(8)
|
(2)
|
Seroquel XR/IR
|
82
|
5
|
6
|
17
|
32
|
27
|
40
|
15
|
20
|
(21)
|
(14)
|
4
|
(15)
|
(13)
|
Movantik/Moventig
|
25
|
(22)
|
(23)
|
-
|
n/m
|
n/m
|
25
|
(17)
|
-
|
n/m
|
n/m
|
-
|
n/m
|
n/m
|
Others
|
31
|
(55)
|
(59)
|
(6)
|
n/m
|
12
|
18
|
9
|
18
|
(46)
|
(81)
|
-
|
(99)
|
n/m
|
Total other medicines
|
731
|
(12)
|
(11)
|
266
|
10
|
19
|
144
|
(6)
|
213
|
(26)
|
(29)
|
108
|
(27)
|
(31)
|
Total Product Sales
|
6,132
|
16
|
18
|
2,123
|
25
|
29
|
2,025
|
17
|
1,139
|
1
|
4
|
845
|
21
|
19
|
|
Q1 2019
|
Actual
|
CER
|
Q2 2019
|
Actual
|
CER
|
Q3 2019
|
Actual
|
CER
|
Q4 2019
|
Actual
|
CER
|
|
$m
|
%
|
%
|
$m
|
%
|
%
|
$m
|
%
|
%
|
$m
|
%
|
%
|
Oncology
|
|
|
|
|
|
|
|
|
|
|
|
|
Tagrisso
|
630
|
6
|
5
|
784
|
24
|
25
|
891
|
14
|
13
|
|
|
|
Imfinzi
|
295
|
13
|
13
|
338
|
15
|
15
|
412
|
22
|
22
|
|
|
|
Lynparza
|
237
|
13
|
13
|
283
|
19
|
20
|
327
|
16
|
15
|
|
|
|
Iressa
|
134
|
20
|
19
|
118
|
(12)
|
(13)
|
91
|
(23)
|
(22)
|
|
|
|
Calquence
|
29
|
21
|
21
|
35
|
21
|
21
|
44
|
27
|
27
|
|
|
|
Faslodex
|
254
|
(6)
|
(6)
|
267
|
5
|
5
|
205
|
(23)
|
(23)
|
|
|
|
Zoladex
|
194
|
7
|
5
|
197
|
2
|
2
|
226
|
15
|
16
|
|
|
|
Arimidex
|
51
|
11
|
9
|
60
|
18
|
20
|
63
|
5
|
5
|
|
|
|
Casodex
|
48
|
4
|
4
|
57
|
19
|
17
|
52
|
(8)
|
(6)
|
|
|
|
Others
|
20
|
(13)
|
(17)
|
28
|
40
|
42
|
20
|
(27)
|
(22)
|
|
|
|
Total Oncology
|
1,892
|
7
|
6
|
2,167
|
15
|
15
|
2,334
|
8
|
8
|
|
|
|
BioPharmaceuticals: CVRM
|
|
|
|
|
|
|
|
|
|
|
|
|
Farxiga
|
349
|
(12)
|
(12)
|
377
|
8
|
9
|
398
|
5
|
5
|
|
|
|
Brilinta
|
348
|
(7)
|
(8)
|
389
|
12
|
12
|
416
|
7
|
8
|
|
|
|
Onglyza
|
153
|
3
|
3
|
116
|
(24)
|
(24)
|
127
|
9
|
11
|
|
|
|
Bydureon
|
142
|
3
|
3
|
141
|
(1)
|
(1)
|
127
|
(10)
|
(10)
|
|
|
|
Byetta
|
30
|
(6)
|
(6)
|
25
|
(17)
|
(17)
|
28
|
10
|
13
|
|
|
|
Other diabetes
|
11
|
(8)
|
(17)
|
11
|
-
|
8
|
14
|
26
|
22
|
|
|
|
Lokelma
|
-
|
-
|
-
|
2
|
-
|
-
|
4
|
n/m
|
n/m
|
|
|
|
Crestor
|
335
|
(5)
|
(6)
|
310
|
(7)
|
(7)
|
337
|
9
|
9
|
|
|
|
Seloken/Toprol-XL
|
225
|
41
|
39
|
168
|
(25)
|
(25)
|
177
|
6
|
8
|
|
|
|
Atacand
|
50
|
(14)
|
(15)
|
56
|
12
|
14
|
55
|
(1)
|
(1)
|
|
|
|
Others
|
71
|
(3)
|
(5)
|
63
|
(11)
|
(8)
|
65
|
4
|
2
|
|
|
|
BioPharmaceuticals: total CVRM
|
1,714
|
(2)
|
(3)
|
1,658
|
(3)
|
(3)
|
1,749
|
5
|
6
|
|
|
|
BioPharmaceuticals: Respiratory
|
|
|
|
|
|
|
|
|
|
|
|
|
Symbicort
|
585
|
(8)
|
(8)
|
585
|
-
|
1
|
613
|
5
|
4
|
|
|
|
Pulmicort
|
383
|
(2)
|
(2)
|
333
|
(13)
|
(13)
|
337
|
1
|
3
|
|
|
|
Fasenra
|
129
|
3
|
2
|
167
|
29
|
30
|
202
|
21
|
21
|
|
|
|
Daliresp/Daxas
|
48
|
(11)
|
(13)
|
56
|
17
|
19
|
53
|
(6)
|
(7)
|
|
|
|
Tudorza/Eklira
|
20
|
5
|
-
|
13
|
(35)
|
(30)
|
17
|
33
|
37
|
|
|
|
Duaklir
|
20
|
(9)
|
(9)
|
17
|
(15)
|
(14)
|
18
|
7
|
5
|
|
|
|
Bevespi
|
10
|
-
|
-
|
10
|
-
|
-
|
10
|
4
|
8
|
|
|
|
Breztri
|
-
|
-
|
-
|
-
|
-
|
-
|
1
|
n/m
|
n/m
|
|
|
|
Others
|
88
|
(20)
|
(19)
|
71
|
(19)
|
(23)
|
67
|
(6)
|
(2)
|
|
|
|
BioPharmaceuticals: total Respiratory
|
1,283
|
(6)
|
(6)
|
1,252
|
(2)
|
(2)
|
1,319
|
5
|
6
|
|
|
|
Other medicines
|
|
|
|
|
|
|
|
|
|
|
|
|
Nexium
|
363
|
(7)
|
3
|
393
|
8
|
9
|
374
|
(5)
|
(4)
|
|
|
|
Losec/Prilosec
|
76
|
27
|
27
|
68
|
(11)
|
(11)
|
73
|
8
|
9
|
|
|
|
Synagis
|
53
|
(79)
|
(90)
|
96
|
81
|
81
|
146
|
52
|
53
|
|
|
|
Seroquel XR/IR
|
37
|
(34)
|
(32)
|
32
|
(14)
|
(13)
|
82
|
n/m
|
n/m
|
|
|
|
Movantik/Moventig
|
25
|
-
|
-
|
22
|
(12)
|
(12)
|
25
|
13
|
13
|
|
|
|
Others
|
22
|
(29)
|
(54)
|
30
|
36
|
50
|
31
|
4
|
(8)
|
|
|
|
Total other medicines
|
576
|
(35)
|
(41)
|
641
|
11
|
13
|
731
|
14
|
14
|
|
|
|
Total Product Sales
|
5,465
|
(5)
|
(7)
|
5,718
|
5
|
5
|
6,132
|
7
|
8
|
|
|
|
|
Q1 2018
|
Actual
|
CER
|
Q2 2018
|
Actual
|
CER
|
Q3 2018
|
Actual
|
CER
|
Q4 2018
|
Actual
|
CER
|
|
$m
|
%
|
%
|
$m
|
%
|
%
|
$m
|
%
|
%
|
$m
|
%
|
%
|
Oncology
|
|
|
|
|
|
|
|
|
|
|
|
|
Tagrisso
|
338
|
11
|
10
|
422
|
25
|
25
|
506
|
20
|
23
|
594
|
17
|
19
|
Iressa
|
132
|
2
|
(1)
|
143
|
8
|
8
|
131
|
(8)
|
(5)
|
112
|
(15)
|
(13)
|
Lynparza
|
119
|
19
|
18
|
150
|
26
|
26
|
169
|
13
|
15
|
209
|
24
|
25
|
Imfinzi
|
62
|
n/m
|
n/m
|
122
|
98
|
98
|
187
|
53
|
52
|
262
|
40
|
41
|
Calquence
|
8
|
n/m
|
n/m
|
12
|
51
|
50
|
18
|
50
|
50
|
24
|
33
|
33
|
Faslodex
|
254
|
7
|
5
|
247
|
(3)
|
(2)
|
258
|
4
|
7
|
269
|
4
|
5
|
Zoladex
|
184
|
(2)
|
(4)
|
192
|
4
|
5
|
194
|
1
|
6
|
182
|
(6)
|
(2)
|
Arimidex
|
54
|
(5)
|
(7)
|
57
|
6
|
6
|
55
|
(4)
|
-
|
46
|
(16)
|
(13)
|
Casodex
|
52
|
(4)
|
(6)
|
52
|
-
|
(2)
|
51
|
(2)
|
4
|
46
|
(10)
|
(8)
|
Others
|
27
|
(7)
|
(20)
|
37
|
37
|
50
|
28
|
(24)
|
(22)
|
23
|
(18)
|
13
|
Total Oncology
|
1,230
|
10
|
8
|
1,434
|
17
|
17
|
1,597
|
11
|
14
|
1,767
|
11
|
13
|
BioPharmaceuticals: CVRM
|
|
|
|
|
|
|
|
|
|
|
|
|
Farxiga
|
299
|
(10)
|
(11)
|
340
|
14
|
15
|
355
|
4
|
7
|
397
|
12
|
13
|
Brilinta
|
293
|
(2)
|
(4)
|
316
|
8
|
9
|
336
|
6
|
9
|
376
|
12
|
13
|
Onglyza
|
129
|
(28)
|
(29)
|
126
|
(2)
|
(2)
|
140
|
11
|
14
|
148
|
6
|
8
|
Bydureon
|
139
|
(5)
|
(5)
|
155
|
12
|
11
|
152
|
(2)
|
(1)
|
138
|
(9)
|
(9)
|
Byetta
|
31
|
(35)
|
(38)
|
29
|
(7)
|
(3)
|
34
|
17
|
17
|
32
|
(6)
|
(6)
|
Symlin
|
9
|
(31)
|
(31)
|
7
|
(22)
|
(22)
|
8
|
14
|
14
|
10
|
25
|
25
|
Crestor
|
389
|
(35)
|
(36)
|
338
|
(13)
|
(12)
|
353
|
4
|
8
|
353
|
-
|
2
|
Seloken/Toprol-XL
|
200
|
19
|
18
|
173
|
(14)
|
(13)
|
179
|
3
|
10
|
160
|
(11)
|
(8)
|
Atacand
|
71
|
(3)
|
(3)
|
66
|
(8)
|
(8)
|
65
|
(2)
|
5
|
58
|
(11)
|
(9)
|
Others
|
85
|
6
|
4
|
73
|
(13)
|
(11)
|
73
|
(3)
|
-
|
75
|
3
|
3
|
BioPharmaceuticals: total CVRM
|
1,645
|
(15)
|
(17)
|
1,623
|
(1)
|
-
|
1,695
|
4
|
8
|
1,747
|
3
|
5
|
BioPharmaceuticals: Respiratory
|
|
|
|
|
|
|
|
|
|
|
|
|
Symbicort
|
634
|
(16)
|
(17)
|
672
|
6
|
6
|
619
|
(8)
|
(5)
|
636
|
3
|
4
|
Pulmicort
|
346
|
(7)
|
(8)
|
287
|
(17)
|
(17)
|
264
|
(8)
|
(4)
|
389
|
47
|
51
|
Daliresp/Daxas
|
38
|
(28)
|
(30)
|
45
|
19
|
22
|
52
|
16
|
18
|
54
|
4
|
4
|
Tudorza/Eklira
|
34
|
(19)
|
(21)
|
39
|
15
|
15
|
18
|
(54)
|
(59)
|
19
|
6
|
11
|
Duaklir
|
28
|
22
|
17
|
22
|
(22)
|
(19)
|
23
|
5
|
5
|
22
|
(4)
|
-
|
Fasenra
|
21
|
n/m
|
n/m
|
65
|
n/m
|
n/m
|
86
|
32
|
34
|
125
|
45
|
46
|
Bevespi
|
5
|
(38)
|
(38)
|
8
|
61
|
60
|
10
|
25
|
25
|
10
|
-
|
-
|
Others
|
75
|
(12)
|
(20)
|
88
|
17
|
16
|
70
|
(20)
|
(13)
|
107
|
53
|
57
|
BioPharmaceuticals: total Respiratory
|
1,181
|
(11)
|
(13)
|
1,226
|
4
|
4
|
1,142
|
(7)
|
(4)
|
1,362
|
19
|
21
|
Other medicines
|
|
|
|
|
|
|
|
|
|
|
|
|
Nexium
|
448
|
5
|
3
|
442
|
(1)
|
(1)
|
422
|
(5)
|
97
|
390
|
(8)
|
(7)
|
Synagis
|
224
|
(4)
|
(4)
|
26
|
(89)
|
(88)
|
164
|
n/m
|
n/m
|
251
|
53
|
n/m
|
Seroquel XR/IR
|
97
|
n/m
|
40
|
131
|
35
|
37
|
77
|
(41)
|
6
|
56
|
(27)
|
(31)
|
Losec/Prilosec
|
69
|
-
|
(4)
|
76
|
10
|
11
|
67
|
(12)
|
85
|
60
|
(10)
|
(8)
|
Movantik/Moventig
|
28
|
(7)
|
(7)
|
24
|
(14)
|
(14)
|
32
|
33
|
n/m
|
25
|
(22)
|
(22)
|
FluMist/Fluenz
|
-
|
n/m
|
n/m
|
-
|
n/m
|
n/m
|
35
|
n/m
|
n/m
|
75
|
n/m
|
n/m
|
Others
|
63
|
(62)
|
(45)
|
48
|
(25)
|
(26)
|
35
|
(27)
|
n/m
|
35
|
-
|
31
|
Total other medicines
|
929
|
(15)
|
(16)
|
747
|
(20)
|
(20)
|
832
|
12
|
15
|
892
|
7
|
22
|
Total Product Sales
|
4,985
|
(9)
|
(11)
|
5,030
|
1
|
1
|
5,266
|
5
|
8
|
5,768
|
10
|
13
|
|
Q1 2017
|
Actual
|
CER
|
Q2 2017
|
Actual
|
CER
|
Q3 2017
|
Actual
|
CER
|
Q4 2017
|
Actual
|
CER
|
|
$m
|
%
|
%
|
$m
|
%
|
%
|
$m
|
%
|
%
|
$m
|
%
|
%
|
Oncology
|
|
|
|
|
|
|
|
|
|
|
|
|
Tagrisso
|
171
|
16
|
19
|
232
|
36
|
34
|
248
|
7
|
5
|
304
|
23
|
22
|
Iressa
|
124
|
5
|
8
|
137
|
10
|
9
|
137
|
-
|
(1)
|
130
|
(5)
|
(6)
|
Lynparza
|
57
|
(8)
|
(6)
|
59
|
4
|
2
|
81
|
37
|
33
|
100
|
23
|
22
|
Imfinzi
|
-
|
-
|
-
|
1
|
n/m
|
n/m
|
-
|
-
|
-
|
18
|
n/m
|
n/m
|
Calquence
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
3
|
n/m
|
n/m
|
Faslodex
|
214
|
(4)
|
(3)
|
248
|
16
|
15
|
241
|
(3)
|
(5)
|
238
|
(1)
|
(1)
|
Zoladex
|
185
|
(21)
|
(12)
|
178
|
(4)
|
(5)
|
185
|
4
|
2
|
187
|
1
|
1
|
Casodex
|
56
|
(7)
|
(2)
|
54
|
(4)
|
(3)
|
51
|
(6)
|
(9)
|
54
|
6
|
6
|
Arimidex
|
52
|
(9)
|
(7)
|
54
|
4
|
4
|
54
|
-
|
(2)
|
57
|
6
|
6
|
Others
|
26
|
(10)
|
(3)
|
30
|
15
|
7
|
29
|
(3)
|
(3)
|
29
|
-
|
3
|
Total Oncology
|
885
|
(5)
|
-
|
993
|
12
|
11
|
1,026
|
3
|
1
|
1,120
|
9
|
9
|
BioPharmaceuticals: total CVRM
|
|
|
|
|
|
|
|
|
|
|
|
|
Brilinta
|
224
|
(5)
|
(4)
|
272
|
21
|
20
|
284
|
4
|
3
|
299
|
5
|
5
|
Farxiga
|
207
|
(13)
|
(13)
|
250
|
21
|
20
|
285
|
14
|
11
|
332
|
16
|
16
|
Onglyza
|
154
|
3
|
3
|
150
|
(3)
|
(3)
|
127
|
(15)
|
(17)
|
180
|
42
|
42
|
Bydureon
|
153
|
8
|
8
|
146
|
(5)
|
(5)
|
128
|
(12)
|
(14)
|
147
|
15
|
15
|
Byetta
|
46
|
(16)
|
(16)
|
43
|
(7)
|
(7)
|
39
|
(9)
|
(9)
|
48
|
23
|
23
|
Symlin
|
14
|
-
|
-
|
11
|
(21)
|
(21)
|
10
|
(9)
|
(9)
|
13
|
30
|
30
|
Qtern
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
5
|
n/m
|
n/m
|
Crestor
|
631
|
-
|
3
|
560
|
(11)
|
(12)
|
580
|
4
|
2
|
594
|
2
|
2
|
Seloken/Toprol-XL
|
186
|
4
|
6
|
181
|
(3)
|
(4)
|
160
|
(12)
|
(14)
|
168
|
5
|
4
|
Atacand
|
75
|
(7)
|
(6)
|
72
|
(4)
|
(5)
|
80
|
11
|
8
|
73
|
(9)
|
(6)
|
Others
|
89
|
3
|
12
|
90
|
1
|
(3)
|
80
|
(11)
|
(12)
|
80
|
-
|
(4)
|
BioPharmaceuticals: total CVRM
|
1,779
|
(2)
|
-
|
1,775
|
-
|
(1)
|
1,773
|
-
|
(2)
|
1,939
|
9
|
9
|
BioPharmaceuticals: Respiratory
|
|
|
|
|
|
|
|
|
|
|
|
|
Symbicort
|
677
|
(9)
|
(7)
|
706
|
4
|
3
|
668
|
(5)
|
(7)
|
752
|
13
|
12
|
Pulmicort
|
337
|
17
|
19
|
226
|
(33)
|
(33)
|
242
|
7
|
5
|
371
|
53
|
51
|
Daliresp/Daxas
|
44
|
7
|
10
|
48
|
9
|
9
|
53
|
10
|
8
|
53
|
-
|
(2)
|
Tudorza/Eklira
|
37
|
3
|
6
|
34
|
(8)
|
(8)
|
37
|
9
|
6
|
42
|
14
|
14
|
Duaklir
|
19
|
-
|
-
|
16
|
(16)
|
(15)
|
21
|
31
|
18
|
23
|
10
|
10
|
Bevespi
|
1
|
(67)
|
(50)
|
3
|
n/m
|
n/m
|
4
|
33
|
33
|
8
|
100
|
100
|
Others
|
66
|
(20)
|
(19)
|
66
|
-
|
(4)
|
67
|
2
|
4
|
85
|
27
|
30
|
BioPharmaceuticals: total Respiratory
|
1,181
|
(2)
|
(1)
|
1,099
|
(7)
|
(8)
|
1,092
|
(1)
|
(3)
|
1,334
|
22
|
21
|
Other medicines
|
|
|
|
|
|
|
|
|
|
|
|
|
Nexium
|
461
|
(6)
|
(4)
|
595
|
29
|
28
|
469
|
(21)
|
(22)
|
427
|
(9)
|
(9)
|
Synagis
|
230
|
(24)
|
(24)
|
70
|
(70)
|
(70)
|
153
|
n/m
|
n/m
|
234
|
53
|
53
|
Seroquel XR/IR
|
104
|
(36)
|
(35)
|
135
|
30
|
30
|
113
|
(16)
|
(16)
|
156
|
38
|
36
|
Losec/Prilosec
|
68
|
15
|
18
|
68
|
-
|
(3)
|
66
|
(3)
|
(6)
|
69
|
5
|
5
|
Movantik/Moventig
|
30
|
15
|
15
|
32
|
7
|
7
|
30
|
(6)
|
(6)
|
30
|
-
|
-
|
FluMist/Fluenz
|
-
|
n/m
|
n/m
|
-
|
-
|
-
|
20
|
n/m
|
n/m
|
58
|
190
|
175
|
Others
|
105
|
(48)
|
44
|
173
|
65
|
n/m
|
140
|
(19)
|
(21)
|
120
|
(14)
|
(15)
|
Total other medicines
|
998
|
(24)
|
(22)
|
1,073
|
8
|
7
|
991
|
(8)
|
(9)
|
1,094
|
10
|
10
|
Total Product Sales
|
4,843
|
(8)
|
(6)
|
4,940
|
2
|
1
|
4,882
|
(1)
|
(3)
|
5,487
|
12
|
12
|
Shareholder information
|
|
|
Announcement of
full year and fourth quarter 2019
results:
14
February 2020
|
|
|
|
|
|
Future
dividends will normally be paid as follows:
|
|
|
First
interim:
|
announced
with half-year and second-quarter results and paid in
September
|
|
Second
interim:
|
announced
with full-year and fourth-quarter results and paid in
March
|
|
|
|
|
Addresses for correspondence
|
||||
|
|
|
|
|
Registered office
|
Registrar and transfer office
|
Swedish Central Securities Depository
|
US depositary
Citibank Shareholder Services
|
|
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge
CB2 0AA
|
Equiniti Limited
Aspect House
Spencer Road
Lancing
West Sussex
BN99 6DA
|
Euroclear Sweden AB PO Box 191
SE-101 23 Stockholm
|
PO Box 43077 Providence
RI 02940-3077
|
|
United Kingdom
|
United Kingdom
|
Sweden
|
United States
|
|
|
|
|
|
|
+44 (0) 20 3749 5000
|
0800 389 1580
|
+46 (0) 8 402 9000
|
+1 (888) 697 8018
|
|
|
+44 (0) 121 415 7033
|
|
+1 (781) 575 4555
|
|
|
|
|
citibank@shareholders-online.com
|
|
|
AstraZeneca
PLC
|
|
By: /s/
Adrian Kemp
|
|
Name:
Adrian Kemp
|
|
Title:
Company Secretary
|